

Third National Health and Nutrition Examination Survey
(NHANES III), 1988-94

NHANES III PARTIAL HOUSEHOLD YOUTH DATA FILE DOCUMENTATION
(VITAMIN, MINERAL, AND MEDICINE USAGE - SECTION K ONLY)

Series 11, No. 2A

April 1998

*Special Note:

(Response to vitamin, mineral & prescription questions)

These files contain the responses to the vitamin/mineral supplement and prescription medicine questions from the Household Adult and Youth questionnaires, respectively. In addition, "Adultx" also contains the antacid and non-prescription pain relief medicine questions from the Household Adult questionnaire. Responses for each of these four questions are listed as one record per respondent. These files do not contain the dietary supplement or prescription medicine product codes. One must use the respondent identification number (SEQN) to link the records in this file with most other files. This file cannot be directly linked to the dietary supplements concentration database files. These files contain overview discussions about the prescription medicine, antacid, and non-prescription medicines sections of the questionnaire as well as specific notes on selected variables.

Table of Contents

Introduction

Guidelines for Data Users.

Survey Description

Sample Design and Analysis Guidelines.

Data Preparation and Processing Procedures

General References

NHANES III Household Youth Data File
 (Vitamin, Mineral, and Medicine Usage)

 General Information

 Data File Index

 Data File Item Descriptions, Codes, Counts, and Notes

 Appendices

Introduction

The National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates data on the health status of U.S. residents. The results of surveys, analyses, and studies are made known through a number of data release mechanisms including publications, mainframe computer data files, CD-ROMs (Search and Retrieval Software, Statistical Export and Tabulation System (SETS)), and the Internet.

The National Health and Nutrition Examination Survey (NHANES) is a periodic survey conducted by NCHS. The third National Health and Nutrition Examination Survey (NHANES III), conducted from 1988 through 1994, was the seventh in a series of these surveys based on a complex, multi-stage sample plan. It was designed to provide national estimates of the health and nutritional status of the United States' civilian, noninstitutionalized population aged two months and older.

The following table summarizes the NHANES III data which are currently available on CD-ROM, including this release.

Table 1. Available NHANES III CD-ROMs

CD-ROM Name	Release Date	Size in Megabytes	Data Files / Description

NHANES III, 1988-94, Series 11, No. 2A, ASCII Version (this release)	April 1998	407	Dietary recall (replacement), electrocardiography, laboratory (additional analytes), and vitamins/medicines data files and documentation
NHANES III, 1988-94, Series 11, No. 1, Revised SETS Version 1.22a	October 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation, plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias
NHANES III, 1988-94, Series 11, No. 1A, ASCII Version	July 1997	454	Adult and youth household questionnaire, dietary recall, examination, and laboratory data files and documentation
NHANES III, 1988-94, Series 11, No. 1, SETS Version 1.22a *	July 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation
NHANES III Reference Manuals and Reports October 1996	October 1996	152	Plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias

* Do not use this CD-ROM It had technical problems and has been superseded by the revised SETS version 1.22a, Series 11, No. 1, released in October 1997.

This release, Series 11, No. 2A, contains previously unreleased data and corrections. Corrections were made to the vitamin/minerals portion of the adult and youth questionnaire data files as well as the dietary recall portion of the examination data file. For the laboratory component, some previously release variables have been augmented with NHANES III Phase 2 data. In addition several new laboratory variables have been added.

The following table shows which public use files contain information from the interview and examination components.

Table 2. Location of the interview and examination components in the NHANES III public use data files

Data File

Topic		HA		HY		EXAM		LAB		DIET		VMS		ECG	
-------	--	----	--	----	--	------	--	-----	--	------	--	-----	--	-----	--

Sample weights	X	X	X	X	.	.	X
Age/race/sex	X	X	X	X	.	.	X
Ethnic background	X	X
Household composition	X	X
Individual characteristics	X	X
Health insurance	X	X
Family background	X	X
Occupation of family head	X	X
Housing characteristics	X	X
Family characteristics	X	X
Orientation	X	X
Health services	X	X
Selected health conditions	X	X	X
Diabetes questions	X
High blood pressure and cholesterol questions	X
Cardiovascular disease questions	X
Musculoskeletal conditions	X
Physical functioning questions	X
Gallbladder disease questions	X

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Kidney conditions	X

Respiratory and allergy questions	X	X
Diet questions	X
Food frequency	X	.	X
Vision questions	X	X
Hearing questions	X	X
Dental care and status	X	X
Tobacco	X	.	X
Occupation	X
Language usage	X	X
Exercise	X
Social support/residence	X
Vitamin/mineral/medicine usage	X	X	X
Blood pressure measurement	X	.	X
Birth	.	X	X
Infant feeding practices/diet	.	X
Motor and social development	.	X
Functional impairment	X	X
School attendance	.	X
Cognitive function	.	X	X

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Alcohol and drug use	.	.	X
Reproductive health	.	.	X

Diagnostic interview schedule	.	.	X
Activity	.	.	X
Physician's examination	.	.	X
Height and weight	.	.	X
Body measurements	.	.	X
Dental examination	.	.	X
Allergy skin test	.	.	X
Audiometry	.	.	X
Tympanometry	.	.	X
WISC and WRAT	.	.	X
Spirometry	.	.	X
Bone densitometry	.	.	X
Gallbladder ultrasonography	.	.	X
Central nervous system function evaluation	.	.	X
Fundus photography	.	.	X
Physical function evaluation	.	.	X
Fasting questions	.	.	.	X	.	.	.

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Laboratory tests on blood and urine	.	.	.	X	.	.	.
Total nutrient intakes	.	.	X
Individual foods	X	.	.

Combination foods	X	.	.
Ingredients	X	.	.
Prescription Medicines	X	X	.	.	.	X	.
Vitamins and Minerals	X	X	.	.	.	X	.
Electrocardiography	X

Data File Definitions

HA - Household Adult Data File
 HY - Household Youth Data File
 EXAM - Examination Data File
 LAB - Laboratory Data File and Second Laboratory Data File
 DIET - Dietary Recall Data Files
 VMS - Vitamin Mineral Supplement Data File
 ECG - Electrocardiography Data File

This document includes the documentation for the NHANES III Partial Household Youth Data File (vitamin, mineral, and medicine usage - section K only) and also contains a general overview of the survey and the use of the data files. The general overview includes five sections. The first section, entitled "Guidelines for Data Users," contains important information about the use of the data files. The second section, "Survey Description," is a brief overview of the survey plan and operation. The third section, "Sample Design and Analysis Guidelines," describes some technical aspects of the sampling plan and discusses some analytic issues particularly related to the use of data from complex sample surveys. The "Data Preparation and Processing Procedures" section describes the editing conventions and the codes used to represent the data. The last and fifth section, "General References," includes a reference list for the survey overview sections of the document.

Public Use Data Files for the third National Health and Nutrition Examination Survey will also be available from the National Technical Information Service (NTIS). A list of NCHS public use data tapes available for purchase from NTIS may be obtained from the Data Dissemination Branch at NCHS. Information regarding a bibliography (on disk) of journal articles citing data from all the NHANES and the availability of NHANES III data in CD-ROM/SETS software format can be obtained from the Data Dissemination Branch at:

Data Dissemination Branch
 National Center for Health Statistics
 Room 1018
 6525 Belcrest Road
 Hyattsville, Maryland 20782

Phone: (301)436-8500

URL: <http://www.cdc.gov/nchswww>

NTIS can be contacted at:

NTIS - Computer Products Office
5285 Port Royal Road
Springfield, Virginia 22161
(703) 487-4807

Copies of all NHANES III questionnaires and data collection forms are included in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996). This publication, along with detailed information on NHANES procedures, interviewing, data collection, quality control techniques, survey design, nonresponse, and sample weighting can be found on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996). Information on how to order this CD-ROM is also available from the Data Dissemination Branch at NCHS at the address and telephone number given above.

GUIDELINES FOR DATA USERS

Please refer to the following important information before analyzing data.

NHANES III Background Documents

- o The Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94, (NCHS, 1994; U.S. DHHS, 1996) provides an overview of the survey and includes copies of the survey forms.
- o The sample design, nonresponse, and analytic guidelines documents on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) discuss the reasons that sample weights and the complex survey design should be taken into account when conducting any analysis.
- o Instruction manuals, laboratory procedures, and other NHANES III reference manuals on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) are also available for further information on the details of the survey.

Analytic Data Set Preparation

- o Most NHANES III survey design and demographic variables are found only on the Adult and Youth Household Data Files available on the first release. In preparing a data set for analysis, other data files must be merged with either or both of these files to obtain many important analytic variables.
- o All of the NHANES III public use data files are linked with the common survey participant identification number (SEQN). Merging information from multiple NHANES III data files using this variable ensures that

the appropriate information for each survey participant is linked correctly.

- o NHANES III public use data files do not have the same number of records on each file. The Household Questionnaire Files (divided into two files, Adult and Youth) contain more records than the Examination Data File because not everyone who was interviewed completed the examination. The Laboratory Data File contains data only for persons aged one year and older. The Individual Foods Data File based on the dietary recall has multiple records for each person rather than the one record per sample person contained in the other data files.
- o For each data file, SAS program code with standard variable names and labels is provided as separate text files on the CD-ROM that contains the data files. This SAS program code can be used to create a SAS data set from the data file.
- o Modifications were made to items in the questionnaires, laboratory, and examination components over the course of the survey; as a result, data may not be available for certain variables for the full six years. In addition, variables may differ by phase since some changes were implemented between phases. Users are encouraged to read the Notes sections of this document carefully for information about changes.
- o Extremely high and low values have been verified whenever possible, and numerous consistency checks have been performed. Nonetheless, users should examine the range and frequency of values before analyzing data.
- o Some data were not ready for release at the time of this publication due to continued processing of the data or analysis of laboratory specimens. A listing of those data are available in the general information section of each data file.
- o Confidential and administrative data are not being released to the public. Additionally, some variables have been recoded to help protect the confidentiality of the survey participants. For example, all age-related variables were recoded to 90+ years for persons who were 90 years of age and older.
- o Some variable names may differ from those used in the Phase 1 NHANES III Provisional Data Release and some variables included in the Phase 1 provisional release may not appear on these files.
- o Although the data files have been edited carefully, errors may be detected. Please notify NCHS staff (301-436-8500) of any errors in the data file or the documentation.

Analytic Considerations

- o NHANES III (1988-94) was designed so that the survey's first three years, 1988-91, its last three years, 1991-94, and the entire six years were national probability samples. Analysts are encouraged to use all six years of survey results.

- o Sample weights are available for analyzing NHANES III data. One of the following three sample weights will be appropriate for nearly all analyses: interviewed sample final weight (WTPFQX6), examined sample final weight (WTPFEX6), and mobile examination center (MEC)- and home-examined sample final weight (WTPFHX6). Choosing which of these sample weights to use in any analysis depends on the variables being used. A good rule of thumb is to use "the least common denominator" approach. In this approach, the user checks the variables of interest. The variable that was collected on the smallest number of persons is the "least common denominator," and the sample weight that applies to that variable is the appropriate one to use for that analysis. For more detailed information, see the Analytic and Reporting Guidelines for NHANES III (U.S. DHHS, 1996).

Referencing or Citing NHANES III Data

- o In publications, please acknowledge NCHS as the original data source. For instance, the reference for the NHANES III Laboratory Data File On this CD-ROM is:

U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Second Laboratory Data File (CD-ROM, Series 11, No. 2A). Hyattsville, MD.: Centers for Disease Control and Prevention, 1998.
- o Please place the acronym "NHANES III" in the titles or abstracts of journal articles and other publications in order to facilitate the retrieval of such materials in bibliographic searches.

SURVEY DESCRIPTION

The third National Health and Nutrition Examination Survey (NHANES III) was the seventh in a series of large health examination surveys conducted in the United States beginning in 1960. Three of these surveys, the National Health Examination Surveys (NHES), were conducted in the 1960's (NCHS, 1965; NCHS, 1967; NCHS, 1969). In 1970, an expanded nutrition component was added to provide data with which to assess nutritional status and dietary practices, and the name was changed to the National Health and Nutrition Examination Survey (Miller, 1973; Engel, 1978; McDowell, 1981). A special survey of Hispanic populations in the United States was conducted during 1982-1984 (NCHS, 1985).

The general structure of the NHANES III sample design was similar to that of the previous NHANES. All of the surveys used complex, multi-stage, stratified, clustered samples of civilian, noninstitutionalized populations. NHANES III was the first NHANES without an upper age limit; in fact, the age range for the survey was two months and older. A home examination option was employed for the first time in order to obtain examination data for very young children and for elderly persons who were

unable to visit the mobile examination center (MEC). The home examination included only a subset of the components used in the full MEC examination since it would have been difficult to collect some types of data in a home setting. A detailed description of design specifications and copies of the data collection forms can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996).

NHANES III was conducted from October 1988 through October 1994 in two phases, each of which comprised a national probability sample. The first phase was conducted from October 18, 1988, through October 24, 1991, at 44 locations. The second phase was conducted from September 20, 1991, through October 15, 1994, at 45 different locations. In NHANES III, 39,695 persons were selected over the six years; of those, 33,994 (86%) were interviewed in their homes. All interviewed persons were invited to the MEC for a medical examination. Seventy-eight percent (30,818) of the selected persons were examined in the MEC, and an additional 493 persons were given a special, limited examination in their homes.

Data collection began with a household interview. Several questionnaires were administered in the household: Household Screener Questionnaire, Family Questionnaire, Household Adult Questionnaire, and Household Youth Questionnaire.

At the MEC, an examination was performed, and five automated questionnaires or interviews were administered: MEC Adult Questionnaire, MEC Youth Questionnaire, MEC Proxy Questionnaire, 24-Hour Dietary Recall, and Dietary Food Frequency (ages 12-16 years). The health examination component included a variety of tests and procedures. The examinee's age at the time of the interview and other factors determined which procedures were administered. Blood and urine specimens were obtained, and a number of tests and measurements were performed including body measurements, spirometry, fundus photography, x-rays, electrocardiography, allergy and glucose tolerance tests, and ultrasonography. Measurements were taken of bone density, hearing, and physical, cognitive, and central nervous system functions. A physician performed a limited standardized medical examination and a dentist performed a standardized dental examination. While some of the blood and urine analyses were performed in the MEC laboratory, most analyses were conducted elsewhere by contract laboratories.

A home examination was conducted for those sample persons aged 2-11 months and aged 20 years or older who were unable to visit the mobile examination center. The home examination consisted of an abbreviated version of the tests and interviews performed in the MEC. Depending on age of the sample person, the components included body measurements, blood pressure, spirometry, venipuncture, physical function evaluation, and a questionnaire to inquire about infant feeding, selected health conditions, cognitive function, tobacco use, and reproductive history.

SAMPLE DESIGN AND ANALYSIS GUIDELINES

Sample Design

The general structure of the NHANES III sample design is the same as that of the previous NHANES. Each of these surveys used a stratified, multi-stage probability design. The major design parameters of the two previous NHANES and the special Hispanic HANES, as well as NHANES III, have been previously summarized (Miller, 1973; McDowell, 1981; NCHS, 1985; NCHS, 1994). The NHANES III sample was designed to be self-weighting within a primary sampling unit (PSU) for subdomains (age, sex, and race-ethnic groups). While the sample was fairly close to self-weighting nationally for each of these subdomain groups, it was not representative of the total population, which includes institutionalized, non-civilian persons that were outside the scope of the survey.

The NHANES III sample represented the total civilian, noninstitutionalized population, two months of age or over, in the 50 states and the District of Columbia of the United States. The first stage of the design consisted of selecting a sample of 81 PSU's that were mostly individual counties. In a few cases, adjacent counties were combined to keep PSU's above a minimum population size. The PSU's were stratified and selected with probability proportional to size (PPS). Thirteen large counties (strata) were chosen with certainty (probability of one). For operational reasons, these 13 certainty PSU's were divided into 21 survey locations. After the 13 certainty strata were designated, the remaining PSU's in the United States were grouped into 34 strata, and two PSU's were selected per stratum (68 survey locations). The selection was done with PPS and without replacement. The NHANES III sample therefore consists of 81 PSU's or 89 locations.

The 89 locations were randomly divided into two groups, one for each phase. The first group consisted of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased estimates (from the point of view of sample selection) of health and nutrition characteristics can be independently produced for both Phase 1 and Phase 2 as well as for both phases combined.

For most of the sample, the second stage of the design consisted of area segments composed of city or suburban blocks, combinations of blocks, or other area segments in places where block statistics were not produced in the 1980 Census. In the first phase of NHANES III, the area segments were used only for a sample of persons who lived in housing units built before 1980. For units built in 1980 and later, the second stage consisted of sets of addresses selected from building permits issued in 1980 or later. These are referred to as "new construction segments." In the second phase, 1990 Census data and maps were used to define the area segments. Because the second phase followed within a few years of the 1990 Census, new construction did not account for a significant part of the sample, and the entire sample came from the area segments.

The third stage of sample selection consisted of households and certain types of group quarters, such as dormitories. All households and eligible group quarters in the sample segments were listed, and a subsample was designated for screening to identify potential sample persons. The subsampling rates enabled production of a national, approximately equal-probability sample of households in most of the United States with

higher rates for the geographic strata with high Mexican-American populations. Within each geographic stratum, there was a nearly equal-probability sample of households across all 89 stands.

Persons within the sample of households or group quarters were the fourth stage of sample selection. All eligible members within a household were listed, and a subsample of individuals was selected based on sex, age, and race or ethnicity. The definitions of the sex, age, race or ethnic classes, subsampling rates, and designation of potential sample persons within screened households were developed to provide approximately self-weighting samples for each subdomain within geographic strata and at the same time to maximize the average number of sample persons per sample household. Previous NHANES indicated that this increased the overall participation rate. Although the exact sample sizes were not known until data collection was completed, estimates were made. Below is a summary of the sample sizes for the full six-year NHANES III at each stage of selection:

Number of PSU's	81
Number of stands (survey locations)	89
Number of segments	2,144
Number of households screened	93,653
Number of households with sample persons	19,528
Number of designated sample persons	39,695
Number of interviewed sample persons	33,994
Number of MEC-examined sample persons	30,818
Number of home-examined sample persons	493

More detailed information on the sample design and weighting and estimation procedures for NHANES III can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996) and in the Analytic and Reporting Guidelines: Third National Health and Nutrition Examination Survey (NHANES III), 1988-94 (U.S. DHHS, 1996).

Analysis Guidelines

Because of the complex survey design used in NHANES III, traditional methods of statistical analysis based on the assumption of a simple random sample are not applicable. Detailed descriptions of this issue and possible analytic methods for analyzing NHANES data have been described earlier (NCHS, 1985; Yetley, 1987; Landis, 1982; Delgado, 1990). Recent analytic and reporting guidelines that should be used for most NHANES III analyses and publications are contained in Analytic and Reporting Guidelines (U.S. DHHS, 1996). These recommendations differ slightly from those used by analysts for previous NHANES surveys. These suggested guidelines provide a framework to users for producing estimates that conform to the analytic design of the survey. All users are strongly urged to review these analytic and reporting guidelines before beginning any analyses of NHANES III data.

It is important to remember that this set of statistical guidelines is not absolute. When conducting analyses, the analyst needs to use his/her subject matter knowledge (including methodological issues) as well as information about the survey design. The more one deviates from the original

analytic categories defined in the sample design, the more important it is to evaluate the results carefully and to interpret the findings cautiously.

In NHANES III, 89 survey locations were randomly divided into two sets or phases, the first consisting of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased national estimates of health and nutrition characteristics can be independently produced for each phase as well as for both phases combined. Computation of national estimates from both phases combined (i.e., total NHANES III) is the preferred option; individual phase estimates may be highly variable. In addition, individual phase estimates are not statistically independent. It is also difficult to evaluate whether differences in individual phase estimates are real or due to methodological differences. That is, differences may be due to changes in sampling methods or data collection methodology over time. At this time, there is no valid statistical test for examining differences between Phase 1 and Phase 2. Therefore, although point estimates can be produced separately for each phase, no test is available to test whether those estimates are significantly different from each other.

NHANES III is based on a complex, multi-stage probability sample design. Several aspects of the NHANES design must be taken into account in data analysis, including the sample weights and the complex survey design. Appropriate sample weights are needed to estimate prevalence, means, medians, and other statistics. Sample weights are used to produce correct population estimates because each sample person does not have the same probability of selection. The sample weights incorporate the differential probabilities of selection and include adjustments for noncoverage and nonresponse. A detailed discussion of nonresponse adjustments and issues related to survey coverage have been published (U.S. DHHS, 1996). With the large oversampling of young children, older persons, black persons, and Mexican-Americans in NHANES III, it is essential that the sample weights be used in all analyses. Otherwise, a misinterpretation of results is highly likely. Other aspects of the design that must be taken into account in data analyses are the strata and PSU pairings from the sample design. These pairings should be used to estimate variances and test for statistical significance. For weighted analyses, analysts can use special computer software packages that use an appropriate method for estimating variances for complex samples such as SUDAAN (Shah, 1995) and WesVarPC (Westat, 1996).

Although initial exploratory analyses may be performed on unweighted data using standard statistical packages and assuming simple random sampling, final analyses should be done on weighted data using appropriate sample weights. A summary of the weighting methodology and the type of sample weights developed for NHANES III is included in Weighting and Estimation Methodology (U.S. DHHS, 1996).

The purpose of weighting the sample data is to permit analysts to produce estimates of statistics that would have been obtained if the entire sampling frame (the United States) had been surveyed. Sample weights can be considered as measures of the number of persons the particular sample observation represents. Weighting takes into account several features of the survey: the specific probabilities of selection for the individual domains that were oversampled as well as nonresponse and differences between the sample and the total U.S. population. Differences between the sample and the population may arise due to sampling variability, differential

undercoverage in the survey among demographic groups, and possibly other types of response errors, such as differential response rates or misclassification errors. Sample weighting in NHANES III was used to:

1. Compensate for differential probabilities of selection among subgroups (i.e., age-sex-race-ethnicity subdomains where persons living in different geographic strata were sampled at different rates);
2. Reduce biases arising from the fact that nonrespondents may be different from those who participate;
3. Bring sample data up to the dimensions of the target population totals;
4. Compensate, to the extent possible, for inadequacies in the sampling frame (resulting from omissions of some housing units in the listing of area segments, omissions of persons with no fixed address, etc.); and
5. To reduce variances in the estimation procedure by using auxiliary information that is known with a high degree of accuracy.

In NHANES III, the sample weighting was carried out in three stages. The first stage involved the computation of weights to compensate for unequal probabilities of selection (objective 1, above). The second stage adjusted for nonresponse (objective 2). The third stage used poststratification of the sample weights to Census Bureau estimates of the U.S. population to accomplish the third, fourth, and fifth objectives simultaneously. In NHANES III, several types of sample weights (see the sample weights table that follows) were computed for the interviewed and examined sample and are included in the NHANES III data file. Also, sample weights were computed separately for Phase 1 (1988-91), Phase 2 (1991-94), and total NHANES III (1988-94) to facilitate analysis of items collected only in Phase 1, only in Phase 2, and over six years of the survey. Three sets of pseudo strata and PSU pairings are provided to use with SUDAAN in variance estimation. Since NHANES III is based on a complex, multi-stage sample design, appropriate sample weights should be used in analyses to produce national estimates of prevalence and associated variances while accounting for unequal probability of selection of sample persons. For example, the final interview weight, WTPFQX6, should be used for analysis of the items or questions from the family or household questionnaires, and the final MEC examination weight, WTPFEX6, should be used for analysis of the questionnaires and measurements administered in the MEC. Furthermore, for a combined analysis of measurements from the MEC examinations and associated medical history questions from the household interview, the final MEC examination weight, WTPFEX6, should be used. We recommend using SUDAAN (Shah, 1995) to estimate statistics of interest and the associated variance. However, one can also use other published methods for variance estimation. Application of SUDAAN and alternative methods, such as the average design effect approach, balance repeated replication (BRR) methods, or jackknife methods for variance estimation, are discussed in Weighting and Estimation Methodology (U.S. DHHS, 1996).

Appropriate Uses of the NHANES III Sample Weights

Final interview weight, WTPFQX6

Use only in conjunction with the sample interviewed at home and with items collected during the household interview.

Final examination (MEC only) weight, WTPFEX6

Use only in conjunction with the MEC-examined sample and with interview and examination items collected at the MEC.

Final MEC+home examination weight, WTPFHX6

Use only in conjunction with the MEC+home-examined sample and with items collected at both the MEC and home.

Final allergy weight, WTPFALG6

Use only in conjunction with the allergy subsample and with items collected as part of the allergy component of the exam.

Final CNS weight, WTPFCNS6

Use only in conjunction with the CNS subsample and with items collected as part of the CNS component of the exam.

Final morning examination (MEC only) subsample weight, WTPFSD6

Use only in conjunction with the MEC-examined persons assigned to the morning subsample and only with items collected in the MEC exam.

Final afternoon/evening examination (MEC only) subsample weight, WTPFMD6

Use only in conjunction with the MEC-examined persons assigned to the afternoon/evening subsample and only with items collected in the MEC exam.

Final morning examination (MEC+home) subsample weight, WTPFHSD6

Use only in conjunction with the MEC- and home-examined persons assigned to the morning subsample and with items collected during the MEC and home examinations.

Final afternoon/evening examination (MEC+home) weight, WTPFHMD6

Use only in conjunction with the MEC- and home-examined persons assigned to the afternoon/evening subsample and with items collected during the MEC and home examinations.

DATA PREPARATION AND PROCESSING PROCEDURES

Automated data collection procedures for the survey were introduced in NHANES III. In the mobile examination centers, data for the interview and examination components were recorded directly onto a computerized data collection form. With the exception of a few independently automated systems, the system was centrally integrated. This operation allowed for ongoing monitoring of much of the data. Before the introduction of the computer-assisted personal interview (CAPI), the household questionnaire data were reviewed manually by field editors and interviewers. CAPI (1992-1994 only) questionnaires featured built-in edits to prevent entering inconsistencies and out-of-range responses. The multi-level data collection and quality control systems are discussed in detail in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996). All interview, laboratory, and examination data were sent to NCHS for final processing.

Guidelines were developed that provided standards for naming variables, filling missing values and coding conventional responses, handling missing records, and standardizing two-part quantity/unit questionnaire variables. NCHS staff, assisted by contract staff, developed data editing specifications that checked data sets for valid codes, ranges, and skip pattern consistencies and examined the consistency of values between interrelated variables. Comments, collected in both interviews and examination components, were reviewed and recoded when possible. Responses to "Other" and "Specify" were recoded either to existing code categories or to new categories. The documentation for each data set includes notes for those variables that have been recoded and standardized and for those variables that differ significantly from what appears in the original data collection instrument. While the data have undergone many quality control and editing procedures, there still may be values that appear extreme or illogical. Values that varied considerably from what was expected were examined by analysts who checked for comments or other responses that might help to clarify unusual values. Generally, values were retained unless they could not possibly be true, in which case they were changed to "Blank but applicable." Therefore, the user must review each data set for extreme or inconsistent values and determine the status of each value for analysis.

Several editing conventions were used in the creation of final analytic data sets:

1. Standardized variables were created to replace all two-part quantity/unit questions using standard conversion factors. Standardized variables have the same name as the variable of the two-part question with an "S" suffix. For instance, MAPF18S (Months received WIC benefits) in the MEC Adult Questionnaire was created from the two-part response option to question F18, "How long did you receive benefits from the WIC program?," using the conversion factor 12 months per year.
2. Recoded variables were created by combining responses from two or more

like variables, or by collapsing responses to create a summary variable for the purpose of confidentiality. Recoded variables have the original variable name with an R suffix. For example, place of birth

variable (HFA6X) in the Family Questionnaire was collapsed to a three level response category (U.S., Mexico, Other) and renamed HFA6XR. Generally, only the recoded variable has been included in the data file.

3. Fill values, a series of one or more digits, were used to represent certain specific conditions or responses. Below is a list of the fill values that were employed. Some of the fill values pertain only to questionnaire data, although 8-fill and blank-fill values are found in all data sets. Other fill values, not included in this list, are used to represent component-specific conditions.

6-fills = Varies/varied. (Questionnaires only)

7-fills = Fewer than the smallest number that could be reported within the question structure (e.g., fewer than one cigarette per day). (Questionnaires only)

8-fills = Blank but applicable/cannot be determined. This means that a respondent was eligible to receive the question, test, or component but did not because of refusal, lack of time, lack of staff, loss of data, broken vial, language barrier, unreliability, or other similar reasons.

9-fills = Don't know. This fill was used only when a respondent did not know the response to a question and said, "I don't know." (Questionnaires only)

Blank fills = Inapplicable. If a respondent was not eligible for a questionnaire, test, or component because of age, gender, or specific reason, the variable was blank-filled. In the questionnaire, if a respondent was not asked a question because of a skip-pattern, variables corresponding to the question were blank-filled. For examination or laboratory components, if a person was excluded by a defined protocol (e.g., screening exclusion questions) and these criteria are included in the data set, then the corresponding variables were blank-filled for that person. For home examinees, variables for examination components and blood tests not performed as part of the home examination protocol were blank-filled.

4. For variables describing discrete data, codes of zero (0) were used to mean "none," "never," or the equivalent. Value labels for which "0" is used include: "has not had," "never regularly," "still taking," or "never stopped using." Unless otherwise labeled, for variables containing continuous data, "zero" means "zero."
5. Where there are logical skip patterns in the flow of the questionnaire or examination component, the skip was indicated by placing the variable label of the skip destination in parentheses as part of the value label of the response generating the skip. For example, in the Physical Function Evaluation, the variable PFPWC (in wheelchair) has a value label, "2 No (PFPSCOOT)" that means that the next item for persons not in a wheelchair would be represented by the variable,

PFPSCOOT.

Variable Nomenclature

A unique name was assigned to every NHANES III variable using a standard convention. By following this naming convention, the origin of each variable is clear, and there is no chance of overlaying similar variables across multiple components. Variables range in length from three to eight characters. The first two variable characters represent the topic (e.g., analyte, questionnaire instrument, examination component) and are listed below alphabetically by topic. For questionnaires administered in the household, the remainder of the variable name following the first two characters indicates the question section and number. For example, data for the response to the Household Adult Questionnaire question B1 are contained in the variable HAB1. For most laboratory and examination variables, as well as some other variables, a "P" in the third position refers to "primary" and the remainder of the variable name is a brief description of the item. For instance, in the Laboratory Data File, information on the length of time the person fasted before the first blood draw is contained in the variable PHPFAST. The variable PHPFAST was derived as follows: characters 1-2 (PH) refer to "phlebotomy," character 3 (P) refers to "primary," characters 4-8 (FAST) refer to an abbreviation for "fasting."

CODE	TOPIC
AT	Alanine aminotransferase (from biochemistry profile)
AM	Albumin (from biochemistry profile)
AP	Alkaline phosphatase (from biochemistry profile)
AL	Allergy skin test
AC	Alpha carotene
AN	Anisocytosis
TM	Antimicrosomal antibodies
TA	Antithyroglobulin antibodies
AA	Apolipoprotein (AI)
AB	Apolipoprotein (B)
AS	Aspartate aminotransferase (from biochemistry profile)
LA	Atypical lymphocyte
AU	Audiometry
BA	Band
BO	Basophil
BS	Basophilic stippling
BC	Beta carotene
BX	Beta cryptoxanthin
BL	Blast
BU	Blood urea nitrogen (BUN) (from biochemistry profile)
BM	Body measurements
BD	Bone densitometry
C1	C-peptide (first venipuncture)
C2	C-peptide (second venipuncture)
CR	C-reactive protein
UD	Cadmium
CN	Central nervous system function evaluation

CL	Chloride (from biochemistry profile)
CO	Cotinine
CE	Creatinine (serum)(from biochemistry profile)
UR	Creatinine (urine)

CODE	TOPIC
DM	Demographic
DE	Dental examination
MQ	Diagnostic interview schedule
DR	Dietary recall (total nutrient intakes)
EO	Eosinophil
EP	Erythrocyte protoporphyrin
FR	Ferritin
FB	Fibrinogen
RB	Folate (RBC)
FO	Folate (serum)
FH	Follicle stimulating hormone (FSH)
FP	Fundus photography
GG	Gamma glutamyl transferase (GGT) (from biochemistry profile)
GU	Gallbladder ultrasonography
GB	Globulin (from biochemistry profile)
G1	Glucose (first venipuncture)
G2	Glucose (second venipuncture)
SG	Glucose (from biochemistry profile)
GH	Glycated hemoglobin
GR	Granulocyte
C3	HCO ₃ (Bicarbonate)(from biochemistry profile)
HD	HDL cholesterol
HP	Helicobacter pylori antibody
HT	Hematocrit
HG	Hemoglobin
AH	Hepatitis A antibody (HAV)
HB	Hepatitis B core antibody (anti-HBc)
SS	Hepatitis B surface antibody (anti-HBs)
SA	Hepatitis B surface antigen (HBsAg)
HC	Hepatitis C antibody (HCV)
DH	Hepatitis D antibody (HDV)
H1	Herpes 1 antibody
H2	Herpes 2 antibody
HX	Home examination (general)
HO	Homocysteine
HF	Household family questionnaire
HA	Household adult questionnaire
HQ	Household questionnaire variables (composite)
HS	Household screener questionnaire
HY	Household youth questionnaire
HZ	Hypochromia
I1	Insulin (first venipuncture)
I2	Insulin (second venipuncture)
UI	Iodine (urine)
FE	Iron
SF	Iron (from biochemistry profile)
LD	Lactate dehydrogenase (from biochemistry profile)
L1	Latex antibody

LC	LDL cholesterol (calculated)
PB	Lead
LP	Lipoprotein (a)
LH	Luteinizing hormone

CODE	TOPIC
LU	Lutein/zeaxanthin
LY	Lycopene
LM	Lymphocyte
MR	Macrocyte
MC	Mean cell hemoglobin (MCH)
MH	Mean cell hemoglobin concentration (MCHC)
MV	Mean cell volume (MCV)
PV	Mean platelet volume
MA	MEC adult questionnaire
MX	MEC examination (general)
FF	Dietary food frequency (ages 12-16 years)
MP	MEC proxy questionnaire
MY	MEC youth questionnaire
ME	Metamyelocyte
MI	Microcyte
MO	Monocyte
MN	Mononuclear cell
ML	Myelocyte
IC	Normalized calcium (derived from ionized calcium)
OS	Osmolality (from biochemistry profile)
PH	Phlebotomy data collected in MEC (e.g., questions)
PS	Phosphorus (from biochemistry profile)
PF	Physical function evaluation
PE	Physician's examination
PL	Platelet
DW	Platelet distribution width
PK	Poikilocytosis
PO	Polychromatophilia
SK	Potassium (from biochemistry profile)
PR	Promyelocyte
RC	Red blood cell count (RBC)
RW	Red cell distribution width (RDW)
RE	Retinyl esters
RF	Rheumatoid factor antibody
RU	Rubella antibody
WT	Sample weights
SE	Selenium
SI	Sickle cell
NA	Sodium (from biochemistry profile)
SH	Spherocyte
SP	Spirometry
SD	Survey design
TT	Target cell
TE	Tetanus
TH	Thyroid Stimulating Hormone (TSH)
T4	Thyroxine
TB	Total bilirubin (from biochemistry profile)
CA	Total calcium
SC	Total calcium (from biochemistry profile)

TC	Total cholesterol
CH	Total cholesterol (from biochemistry profile)
TI	Total iron binding capacity (TIBC)
TP	Total protein (from biochemistry profile)
TX	Toxic granulation

CODE	TOPIC
TO	Toxoplasmosis antibody
PX	Transferrin saturation
TG	Triglycerides
TR	Triglycerides (from biochemistry profile)
TY	Tympanometry
UA	Uric acid (from biochemistry profile)
UB	Urinary albumin
VU	Vacuolated cells
VR	Varicella antibody
VA	Vitamin A
VB	Vitamin B12
VC	Vitamin C
VD	Vitamin D
VE	Vitamin E
WC	White blood cell count (WBC)
WW	WISC/WRAT cognitive test

GENERAL REFERENCES

- Delgado JL, Johnson CL, Roy I, Trevino FM. Hispanic Health and Nutrition Examination Survey: methodological considerations. Amer J Pub Health 80(suppl.):6-10. 1990.
- Engel A, Murphy RS, Maurer K, Collins E. Plan and operation of the HANES I Augmentation Survey of Adults 25-74 Years, United States, 1974-75. National Center for Health Statistics. Vital Health Stat 1(14). 1978.
- Freeman DH, Freeman JL, Brock DB, Koch GG. Strategies in the multivariate analysis of data from complex surveys II: an application to the United States National Health Interview Survey. Int Stat Rev 40(3):317-30. 1976.
- Khare M, Mohadjer LK, Ezzati-Rice TM, Waksberg J. An evaluation of nonresponse bias in NHANES III (1988-91). 1994 Proceedings of the Survey Research Methods section of the American Statistical Association. 1994.
- Landis JR, Lepkowski JM, Eklund SA, Stehouwer SA. A statistical methodology for analyzing data from a complex survey, the first National Health and Nutrition Examination Survey. National Center for Health Statistics. Vital Health Stat 2(92). 1982.
- McDowell A, Engel A, Massey JT, Maurer K. Plan and operation of the second National Health and Nutrition Examination Survey, 1976-80. National Center for Health Statistics. Vital Health Stat 1(15). 1981.

Miller HW. Plan and operation of the Health and Nutrition Examination Survey, United States, 1971-1973. National Center for Health Statistics. Vital Health Stat 1(10a) and (10b). 1973.

National Center for Health Statistics. Plan and initial program of the Health Examination Survey. Vital Health Stat 1(4). 1965.

National Center for Health Statistics. Plan and operation of a health examination survey of U.S. youths 12-17 years of age. Vital Health Stat 1(8). 1969.

National Center for Health Statistics. Plan and operation of the Hispanic Health and Nutrition Examination Survey, 1982-84. Vital Health Stat 1(19). 1985.

National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital Health Stat 1(32). 1994.

National Center for Health Statistics. Plan, operation, and response results of a program of children's examinations. Vital Health Stat 1(5). 1967.

Shah BV, Barnwell BG, Bieler GS. SUDAAN User's Manual: Software for Analysis of Correlated Data. Research Triangle Park, NC: Research Triangle Institute. Release 6.04. 1995.

Skinner CJ. Aggregated analysis: standard errors and significance tests. In: Skinner CJ, Holt D, Smith TMF, eds. Analysis of complex surveys. New York: John Wiley and Sons, Inc. 1989.

U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. NHANES III reference manuals and reports (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996. Available from National Technical Information Service (NTIS), Springfield, VA. Acrobat .PDF format; includes access software: Adobe Systems, Inc. Acrobat Reader 2.1.

Westat, Inc. A User's Guide to WesVarPC. Rockville, MD. Westat, Inc. 1996.

Yetley E, Johnson C. Nutritional applications of the Health and Nutrition Examination Surveys (HANES). Annu Rev Nutr 7:441-63. 1987.

NHANES III Partial Household Youth Data File
(Vitamin, Mineral, and Medicine Usage - Section K Only)

General Information

Household Questionnaire: Prescription Medicines

During the household interview survey respondents were asked a series of questions about prescription medicines used during in the past month. A proxy, usually a child's parent or guardian, provided this information for children 2 months to 16 years of age. If respondents or proxy respondents reported taking a prescription medicine, they were asked the number of prescription medicines they took. For each medication reported, the interviewer asked to see the medication container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Respondents or proxies were also asked to describe the health problem for which they took the medicine, and how long they had been taking the medicine. Analysts should be aware, however, that there were respondents or proxies who reported taking prescription medicines, but did not answer some or all of the remaining questions about the prescription medicines. In other cases respondents or proxies reported a health problem and/or duration they took a medication, but did not know the name of the medication or NCHS staff could not identify the name. In both cases, the missing fields are coded as either "blank but applicable" (8-fill) or "don't know" (9-fill), whichever was applicable.

Some prescription medicines originally reported in the supplements, antacid, or non-prescription drug sections of the questionnaire were moved to the prescription medicine section of the questionnaire. Some prescribed vitamin and/or mineral supplements, originally reported in the prescription medicines section, could be considered both a drug or a supplement (e.g., calciferol, niacin, calcitriol, and potassium). These products were copied to the dietary supplements section.

In general, non-prescription medications that were reported in the prescription drug section of the household adult questionnaire were moved to the non-prescription medications section (the expanded non-prescription pain relief medications section to be described later), but those medications reported on the household youth questionnaire were deleted since a non-prescription medications section was not included in the youth questionnaire. However, for both the household youth and adult questionnaires if a particular medication reported in the prescription medication section of the questionnaire was available in both prescription and non-prescription strengths (e.g., ibuprofen), the staff assumed it was a prescription medication and left it in this section. On the adult questionnaire, aspirin was moved to the non-prescription medications sections unless the strength or brand name reported was only available by prescription (e.g., "Zorprin"). Also on the household adult questionnaire, prescription antacids were left in this section, but over-the-counter antacids were moved to the antacid section unless, at the time of the survey, the antacid was only available by prescription (e.g., "Zantac").

Each prescription medicine name reported in the survey was located in the Physicians' GenRx, and assigned the standard generic name and 4-digit generic code for that product. However, for five prescription medications a generic name or code did not exist. The NCHS staff created product codes for these medicines. See the notes associated with this variable in the data file layout for a detailed discussion of the prescription medication product code. A list of the standardized generic prescription medication names and their associated product codes can be found in Appendix 1.

In some cases it may appear as though respondents reported the same

prescription medicine more than once. That is, the same generic prescription medicine name and product code may be listed more than once. There are a number of reasons for these duplications. Respondents may have reported different brand name medicines which had the same generic name (e.g., "Adalat" vs. "Procardia"), or the medicines may have been different forms (e.g., tablet vs. patch), strengths (e.g., 20 mg vs. 30 mg), or dosages (e.g., once a day vs. twice a day) of the same product. Based on the information collected when respondents reported different brand names of the same generic product it was difficult to determine if these were duplicate listings or the individuals had taken more than one product in the month. Also, since descriptive information on the form, strength, and dosage of prescription medicines was not collected it was difficult to determine if these were reasons for the duplications. Hence, most of the duplicates have been left in the file.

Up to three drug class codes (i.e., primary, secondary, and tertiary) were assigned to each prescription medication that a respondent reported. These 4-digit codes came from the National Drug Code Directory prepared by the Product Information Management Branch of the Food and Drug Administration. See Appendix 2 for a listing of the drug class codes and descriptions.

Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. For example, all cardiovascular drugs that were beta-adrenergic blocking agents were assigned the drug class code for "Beta blockers" (512). Additional drug class codes were assigned based on the reason the respondent reported for taking the medication, for example, "Antiarrhythmics" (502) or "Antihypertensives" (506). Another example is the drug "Diazepam". The primary drug class code for "Diazepam" is sedative or hypnotic (626). If the respondent reported any of the following reasons for taking the drug, the drug class fields were also coded with these reasons: anxiety (627), muscle spasms (1373), or convulsive disorder (1374). If the reason the respondent gave did not relate to any of the actions of the drug, then only the medication-specific class code was assigned.

There are instances where the prescription medication product code and standard generic name are coded as "blank but applicable" (8-fill), but there is a valid primary drug class code. In these cases, the medication name and/or health condition that the respondent reported provided sufficient information in order to assign a drug class code.

ICD-9-CM codes were used to classify the health problem respondents gave for taking the prescription medicine. In general, the health problems were coded to the fourth digit ICD-9-CM level of specificity, but in some cases the highest level of specificity was only three digits and in other cases the level of specificity was five digits. See the notes associated with this variable in the data file layout for a detailed discussion of the ICD-9-CM codes. See Appendix 3 for a listing of the ICD-9-CM codes and descriptions.

As described earlier there were respondents who reported taking a prescription medicine but did not give a reason why they took the medicine. In these instances the ICD-9 codes are coded as "blank but applicable" (8-fill) or "don't know" (9-fill). On the other hand, there were respondents who reported a health problem but did not report the medication they were taking or NCHS staff could not identify it. In these cases the prescription medication product code, and sometimes the drug class codes, are coded as "blank but applicable" (8-fill) or "don't know" (9-fill), but there is an ICD-9 code listed.

For each prescription medicine reported, respondents were also asked how long they had been taking the medicine. See the notes associated with this variable in the data file layout for a detailed discussion of this variable. When medicines were moved from the dietary supplements section to the prescription medicine section some of the categories for duration of use did not correspond.

A response of "less than one month" in the supplements section was changed to "blank but applicable" (8-fill) in prescription medicine section.

NHANES III Partial Household Youth Data File Index

Description	Variable Name	Positions
HOUSEHOLD SCREENER QUESTIONNAIRE (HSQ)		
GENERAL INFORMATION		
Respondent identification number	SEQN	1-5
HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)		
SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE		
Taken vitamins/minerals in past month	HYK1A	6
Taken prescriptn medicines in past month	HYK1B	7
How many vitamins/minerals taken	HYK2A	8-9
How many prescription medicines taken	HYK2B	10-11
Certainty index code-1st	HYK3CG	12-13
Product class-1st	HYK3DG	14-15
How often did -- take in past month-1st	HYK6SG	16-19
How long been taking (month)-1st	HYK8SG	20-23
Certainty index code-2nd	HYK3CH	24-25
Product class-2nd	HYK3DH	26-27
How often did -- take in past month-2nd	HYK6SH	28-31
How long been taking (month)-2nd	HYK8SH	32-35
Certainty index code-3rd	HYK3CI	36-37
Product class-3rd	HYK3DI	38-39
How often did -- take in past month-3rd	HYK6SI	40-43
How long been taking (month)-3rd	HYK8SI	44-47
Certainty index code-4th	HYK3CJ	48-49
Product class-4th	HYK3DJ	50-51
How often did -- take in past month-4th	HYK6SJ	52-55
How long been taking (month)-4th	HYK8SJ	56-59
Certainty index code-5th	HYK3CK	60-61
Product class-5th	HYK3DK	62-63
How often did -- take in past month-5th	HYK6SK	64-67
How long been taking (month)-5th	HYK8SK	68-71
Certainty index code-6th	HYK3CL	72-73
Product class-6th	HYK3DL	74-75
How often did -- take in past month-6th	HYK6SL	76-79

How long been taking (month)-6th HYK8SL 80-83

NHANES III Partial Household Youth Data File Index

Description	Variable Name	Positions
Certainty index code-7th	HYK3CM	84-85
Product class-7th	HYK3DM	86-87
How often did -- take in past month-7th	HYK6SM	88-91
How long been taking (month)-7th	HYK8SM	92-95
Certainty index code-8th	HYK3CN	96-97
Product class-8th	HYK3DN	98-99
How often did -- take in past month-8th	HYK6SN	100-103
How long been taking (month)-8th	HYK8SN	104-107
Certainty index code-9th	HYK3CO	108-109
Product class-9th	HYK3DO	110-111
How often did -- take in past month-9th	HYK6SO	112-115
How long been taking (month)-9th	HYK8SO	116-119
Certainty index code-10th	HYK3CP	120-121
Product class-10th	HYK3DP	122-123
How often did -- take in past month-10th	HYK6SP	124-127
How long been taking (month)-10th	HYK8SP	128-131
Primary drug class code-1st	HYK9DG	132-135
Secondary drug class code-1st	HYK9EG	136-139
Tertiary drug class code-1st	HYK9FG	140-143
ICD-9-CM code-1st	HYK11AG	144-149
For how long been taking (days)-1st	HYK12SG	150-154
Primary drug class code-2nd	HYK9DH	155-158
Secondary drug class code-2nd	HYK9EH	159-162
Tertiary drug class code-2nd	HYK9FH	163-166
ICD-9-CM code-2nd	HYK11AH	167-172
For how long been taking (days)-2nd	HYK12SH	173-177
Primary drug class code-3rd	HYK9DI	178-181
Secondary drug class code-3rd	HYK9EI	182-185
Tertiary drug class code-3rd	HYK9FI	186-189
ICD-9-CM code-3rd	HYK11AI	190-195
For how long been taking (days)-3rd	HYK12SI	196-200
Primary drug class code-4th	HYK9DJ	201-204
Secondary drug class code-4th	HYK9EJ	205-208
Tertiary drug class code-4th	HYK9FJ	209-212
ICD-9-CM code-4th	HYK11AJ	213-218
For how long been taking (days)-4th	HYK12SJ	219-223
Primary drug class code-5th	HYK9DK	224-227
Secondary drug class code-5th	HYK9EK	228-231
Tertiary drug class code-5th	HYK9FK	232-235

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
-----------------------	--------	------------------------------	-------

The following questions concern --'s use of vitamins, minerals, and medicines in the past month.

6 HYK1A		Has -- taken any vitamins or minerals in the past month? Please include those that are prescribed by a doctor or dentist and those that are not prescribed. DO NOT INCLUDE TOPICAL VITAMINS.	
	4283	1 Yes	
	9605	2 No	
	45	8 Blank but applicable	
	11	9 Don't know	

7 HYK1B		Has -- taken or used any medicines for which a doctor's or dentist's prescription is needed, in the past month? This includes any products which cannot be obtained without a doctor's or dentist's prescription. Include those medicines you may have already mentioned. DO NOT INCLUDE PRESCRIPTION VITAMINS WHICH SHOULD BE RECORDED AT HYK1A.	
	2748	1 Yes	
	11128	2 No	
	63	8 Blank but applicable	
	5	9 Don't know	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
-----------------------	--------	------------------------------	-------

CHECK ITEM. REFER TO RESPONSES IN HYK1A-1B. IF ANY YES: May I see the containers for all of the (vitamins

and minerals/prescription medicines) --
took in the past month?

8-9		Number of vitamins/minerals reported		
HYK2A	4283	01-10		
	45	88	Blank but applicable	
	9616	Blank		
10-11		Number of prescription medicines reported		
HYK2B	2748	01-09		
	63	88	Blank but applicable	
	11133	Blank		
12-13		Certainty index code		See note
HYK3CG		(1st supplement reported)		
	2475	01	Match with high degree of certainty	
	630	02	Match with reasonable degree of certainty	
	388	03	Match to product ingredients only (not amounts)	
	619	04	Match to product type only (not exact amounts)	
	70	05	No match - unidentified supplement	
	80	06	No match - too vague to identify as a supplement	
	66	88	Blank but applicable	
	9616	Blank		

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions		Item description	
SAS name	Counts	and code	Notes
14-15		Product class	See note
HYK3DG		(1st supplement reported)	
	159	01 Vitamin supplement - single nutrient	
	2101	02 Vitamin supplement - multiple nutrient	
	294	03 Mineral supplement - single nutrient	
	9	04 Mineral supplement - multiple nutrient	
	1548	05 Vitamin - mineral combination	
	19	06 Other dietary supplement with	

		vitamin(s)/mineral(s)
15	07	Other dietary supplement
183	88	Blank but applicable
9616		Blank

16-19 HYK6SG		How often did -- take (PRODUCT) in the past month? (1st supplement reported)	See note
	4126	0001-0638	
	195	8888 Blank but applicable	
	7	9999 Don't know	
	9616	Blank	

20-23 HYK8SG		For how long has -- been taking this type of product? (months) (1st supplement reported)	See note
	3934	0001-0192	
	291	7777 Less than one month	
	81	8888 Blank but applicable	
	22	9999 Don't know	
	9616	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes

24-25 HYK3CH		Certainty index code (2nd supplement reported)	See note
	128	01 Match with high degree of certainty	
	25	02 Match with reasonable degree of certainty	
	168	03 Match to product ingredients only (not amounts)	
	56	04 Match to product type only (not exact amounts)	
	8	05 No match - unidentified supplement	
	5	06 No match - too vague to identify as a supplement	
	46	88 Blank but applicable	
	13508	Blank	
26-27 HYK3DH		Product class (2nd supplement reported)	See note
	110	01 Vitamin supplement - single nutrient	

100	02	Vitamin supplement - multiple nutrient
78	03	Mineral supplement - single nutrient
3	04	Mineral supplement - multiple nutrient
73	05	Vitamin - mineral combination
3	06	Other dietary supplement with vitamin(s)/mineral(s)
12	07	Other dietary supplement
57	88	Blank but applicable
13508		Blank

28-31 HYK6SH		How often did -- take (PRODUCT) in the past month? (2nd supplement reported)	See note
359		0001-0456	
76	8888	Blank but applicable	
1	9999	Don't know	
13508		Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
32-35 HYK8SH		For how long has -- been taking this type of product? (months) (2nd supplement reported)	See note
	355	0001-0192	
	32	7777 Less than one month	
	49	8888 Blank but applicable	
	13508	Blank	
36-37 HYK3CI		Certainty index code (3rd supplement reported)	See note
	12	01 Match with high degree of certainty	
	1	02 Match with reasonable degree of certainty	
	28	03 Match to product ingredients only (not amounts)	
	7	04 Match to product type only (not exact amounts)	
	1	05 No match - unidentified supplement	
	1	06 No match - too vague to identify as a supplement	

	46	88	Blank but applicable	
	13848		Blank	
38-39 HYK3DI			Product class (3rd supplement reported)	See note
	29	01	Vitamin supplement - single nutrient	
	9	02	Vitamin supplement - multiple nutrient	
	3	03	Mineral supplement - single nutrient	
	2	05	Vitamin - mineral combination	
	2	06	Other dietary supplement with vitamin(s)/mineral(s)	
	4	07	Other dietary supplement	
	47	88	Blank but applicable	
	13848		Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes

40-43 HYK6SI		How often did -- take (PRODUCT) in the past month? (3rd supplement reported)	See note
	46	0002-0486	
	48	8888 Blank but applicable	
	2	9999 Don't know	
	13848	Blank	
44-47 HYK8SI		For how long has -- been taking this type of product? (months) (3rd supplement reported)	See note
	49	0001-0168	
	1	7777 Less than one month	
	46	8888 Blank but applicable	
	13848	Blank	
48-49 HYK3CJ		Certainty index code (4th supplement reported)	See note
	4	01 Match with high degree of certainty	
	1	02 Match with reasonable degree of certainty	
	17	03 Match to product ingredients only (not amounts)	

1	06	No match - too vague to identify as a supplement
46	88	Blank but applicable
13875		Blank

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes

50-51 HYK3DJ		Product class (4th supplement reported)	See note
	15	01 Vitamin supplement - single nutrient	
	1	02 Vitamin supplement - multiple nutrient	
	3	03 Mineral supplement - single nutrient	
	1	05 Vitamin - mineral combination	
	1	06 Other dietary supplement with vitamin(s)/mineral(s)	
	1	07 Other dietary supplement	
	47	88 Blank but applicable	
	13875	Blank	
52-55 HYK6SJ		How often did -- take (PRODUCT) in the past month? (4th supplement reported)	See note
	21	0002-0030	
	46	8888 Blank but applicable	
	2	9999 Don't know	
	13875	Blank	
56-59 HYK8SJ		For how long has -- been taking this type of product? (months) (4th supplement reported)	See note
	23	0002-0144	
	46	8888 Blank but applicable	
	13875	Blank	
60-61 HYK3CK		Certainty index code (5th supplement reported)	See note
	1	01 Match with high degree of certainty	
	7	03 Match to product ingredients only (not amounts)	
	1	06 No match - too vague to identify	

		as a supplement
45	88	Blank but applicable
13890		Blank

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
62-63 HYK3DK		Product class (5th supplement reported)	See note
	6	01 Vitamin supplement - single nutrient	
	1	03 Mineral supplement - single nutrient	
	1	07 Other dietary supplement	
	46	88 Blank but applicable	
	13890	Blank	
64-67 HYK6SK		How often did -- take (PRODUCT) in the past month? (5th supplement reported)	See note
	7	0002-0061	
	45	8888 Blank but applicable	
	2	9999 Don't know	
	13890	Blank	
68-71 HYK8SK		For how long has -- been taking this type of product? (months) (5th supplement reported)	See note
	9	0002-0120	
	45	8888 Blank but applicable	
	13890	Blank	
72-73 HYK3CL		Certainty index code (6th supplement reported)	See note
	1	03 Match to product ingredients only (not amounts)	
	45	88 Blank but applicable	
	13898	Blank	
74-75 HYK3DL		Product class (6th supplement reported)	See note
	1	05 Vitamin - mineral combination	
	45	88 Blank but applicable	
	13898	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
76-79 HYK6SL		How often did -- take (PRODUCT) in the past month? (6th supplement reported)	See note
	1	0009	
	45	8888 Blank but applicable	
	13898	Blank	
80-83 HYK8SL		For how long has -- been taking this type of product? (months) (6th supplement reported)	See note
	1	0018	
	45	8888 Blank but applicable	
	13898	Blank	
84-85 HYK3CM		Certainty index code (7th supplement reported)	See note
	1	04 Match to product type only (not exact amounts)	
	45	88 Blank but applicable	
	13898	Blank	
86-87 HYK3DM		Product class (7th supplement reported)	See note
	1	05 Vitamin - mineral combination	
	45	88 Blank but applicable	
	13898	Blank	
88-91 HYK6SM		How often did -- take (PRODUCT) in the past month? (7th supplement reported)	See note
	1	0013	
	45	8888 Blank but applicable	
	13898	Blank	
92-95 HYK8SM		For how long has -- been taking this type of product? (months) (7th supplement reported)	See note
	1	0012	
	45	8888 Blank but applicable	
	13898	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
96-97 HYK3CN		Certainty index code (8th supplement reported)	See note
	1	03 Match to product ingredients only (not amounts)	
	45	88 Blank but applicable	
	13898	Blank	
98-99 HYK3DN		Product class (8th supplement reported)	See note
	1	01 Vitamin supplement - single nutrient	
	45	88 Blank but applicable	
	13898	Blank	
100-103 HYK6SN		How often did -- take (PRODUCT) in the past month? (8th supplement reported)	See note
	1	0001	
	45	8888 Blank but applicable	
	13898	Blank	
104-107 HYK8SN		For how long has -- been taking this type of product? (months) (8th supplement reported)	See note
	1	0009	
	45	8888 Blank but applicable	
	13898	Blank	
108-109 HYK3CO		Certainty index code (9th supplement reported)	See note
	1	03 Match to product ingredients only (not amounts)	
	45	88 Blank but applicable	
	13898	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
110-111 HYK3DO		Product class (9th supplement reported)	See note
	1	01 Vitamin supplement - single nutrient	
	45	88 Blank but applicable	
	13898	Blank	
112-115 HYK6SO		How often did -- take (PRODUCT) in the past month? (9th supplement reported)	See note
	1	0009	
	45	8888 Blank but applicable	
	13898	Blank	
116-119 HYK8SO		For how long has -- been taking this type of product? (months) (9th supplement reported)	See note
	1	0003	
	45	8888 Blank but applicable	
	13898	Blank	
120-121 HYK3CP		Certainty index code (10th supplement reported)	See note
	1	03 Match to product ingredients only (not amounts)	
	45	88 Blank but applicable	
	13898	Blank	
122-123 HYK3DP		Product class (10th supplement reported)	See note
	1	03 Mineral supplement - single nutrient	
	45	88 Blank but applicable	
	13898	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
124-127 HYK6SP		How often did -- take (PRODUCT) in the past month? (10th supplement reported)	See note
	1	0002	
	45	8888 Blank but applicable	
	13898	Blank	
128-131 HYK8SP		For how long has -- been taking this type of product? (months) (10th supplement reported)	See note
	1	0009	
	45	8888 Blank but applicable	
	13898	Blank	
132-135 HYK9DG		Primary drug class code (1st medication reported)	See note
	2573	0100-2098	
	178	8888 Blank but applicable	
	60	9999 Don't know	
	11133	Blank	
136-139 HYK9EG		Secondary drug class code (1st medication reported)	See note
	76	0121-1729	
	2675	8888 Blank but applicable	
	60	9999 Don't know	
	11133	Blank	
140-143 HYK9FG		Tertiary drug class code (1st medication reported)	See note
	6	1268-1271	
	2745	8888 Blank but applicable	
	60	9999 Don't know	
	11133	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
144-149		ICD-9-CM code	See note

HYK11AG		(1st medication reported)	
	2680	V01.1-995.69	
	129	888888 Blank but applicable	
	2	999999 Don't know	
	11133	Blank	
150-154 HYK12SG		For how long has -- been taking or using (MEDICINE)? (days) (1st medication reported)	See note
	2673	00001-04380	
	133	888888 Blank but applicable	
	5	999999 Don't know	
	11133	Blank	
155-158 HYK9DH		Primary drug class code (2nd medication reported)	See note
	839	0300-1947	
	88	8888 Blank but applicable	
	20	9999 Don't know	
	12997	Blank	
159-162 HYK9EH		Secondary drug class code (2nd medication reported)	See note
	24	0353-1670	
	903	8888 Blank but applicable	
	20	9999 Don't know	
	12997	Blank	
163-166 HYK9FH		Tertiary drug class code (2nd medication reported)	See note
	4	1270-1271	
	923	8888 Blank but applicable	
	20	9999 Don't know	
	12997	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes

167-172 HYK11AH		ICD-9-CM code (2nd medication reported)	See note
	871	V07.9-995.3	
	73	888888 Blank but applicable	
	3	999999 Don't know	
	12997	Blank	

173-177 HYK12SH		For how long has -- been taking or using (MEDICINE)? (days) (2nd medication reported)	See note
	865	00001-05840	
	76	88888 Blank but applicable	
	6	99999 Don't know	
	12997	Blank	
178-181 HYK9DI		Primary drug class code (3rd medication reported)	See note
	252	0100-2095	
	64	8888 Blank but applicable	
	6	9999 Don't know	
	13622	Blank	
182-185 HYK9EI		Secondary drug class code (3rd medication reported)	See note
	9	0353-1271	
	307	8888 Blank but applicable	
	6	9999 Don't know	
	13622	Blank	
186-189 HYK9FI		Tertiary drug class code (3rd medication reported)	See note
	2	1271	
	314	8888 Blank but applicable	
	6	9999 Don't know	
	13622	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
190-195 HYK11AI		ICD-9-CM code (3rd medication reported)	See note
	255	033.9-995.3	
	64	888888 Blank but applicable	
	3	999999 Don't know	
	13622	Blank	
196-200 HYK12SI		For how long has -- been taking or using (MEDICINE)? (days) (3rd medication reported)	See note
	256	00001-04745	

	65	88888 Blank but applicable	
	1	99999 Don't know	
	13622	Blank	
201-204 HYK9DJ		Primary drug class code (4th medication reported)	See note
	68	0346-1947	
	65	8888 Blank but applicable	
	1	9999 Don't know	
	13810	Blank	
205-208 HYK9EJ		Secondary drug class code (4th medication reported)	See note
	3	1271-1724	
	130	8888 Blank but applicable	
	1	9999 Don't know	
	13810	Blank	
209-212 HYK9FJ		Tertiary drug class code (4th medication reported)	See note
	1	1270	
	132	8888 Blank but applicable	
	1	9999 Don't know	
	13810	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
213-218 HYK11AJ		ICD-9-CM code (4th medication reported)	See note
	69	033.9-995.3	
	65	888888 Blank but applicable	
	13810	Blank	
219-223 HYK12SJ		For how long has -- been taking or using (MEDICINE)? (days) (4th medication reported)	See note
	69	00002-04015	
	64	88888 Blank but applicable	
	1	99999 Don't know	
	13810	Blank	
224-227 HYK9DK		Primary drug class code (5th medication reported)	See note

	25	0346-1947	
	65	8888 Blank but applicable	
	13854	Blank	
228-231 HYK9EK		Secondary drug class code (5th medication reported)	See note
	90	8888 Blank but applicable	
	13854	Blank	
232-235 HYK9FK		Tertiary drug class code (5th medication reported)	See note
	90	8888 Blank but applicable	
	13854	Blank	
236-241 HYK11AK		ICD-9-CM code (5th medication reported)	See note
	26	V07.9-995.3	
	64	888888 Blank but applicable	
	13854	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
242-246 HYK12SK		For how long has -- been taking or using (MEDICINE)? (days) (5th medication reported)	See note
	26	00007-04015	
	64	88888 Blank but applicable	
	13854	Blank	
247-250 HYK9DL		Primary drug class code (6th medication reported)	See note
	12	0348-1947	
	63	8888 Blank but applicable	
	13869	Blank	
251-254 HYK9EL		Secondary drug class code (6th medication reported)	See note
	75	8888 Blank but applicable	
	13869	Blank	
255-258 HYK9FL		Tertiary drug class code (6th medication reported)	See note
	75	8888 Blank but applicable	

	13869	Blank	
259-264 HYK11AL		ICD-9-CM code (6th medication reported)	See note
	12	382.9-786.09	
	63	888888 Blank but applicable	
	13869	Blank	
265-269 HYK12SL		For how long has -- been taking or using (MEDICINE)? (days) (6th medication reported)	See note
	12	00152-04015	
	63	88888 Blank but applicable	
	13869	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
270-273 HYK9DM		Primary drug class code (7th medication reported)	See note
	5	0879-1947	
	64	8888 Blank but applicable	
	13875	Blank	
274-277 HYK9EM		Secondary drug class code (7th medication reported)	See note
	69	8888 Blank but applicable	
	13875	Blank	
278-281 HYK9FM		Tertiary drug class code (7th medication reported)	See note
	69	8888 Blank but applicable	
	13875	Blank	
282-287 HYK11AM		ICD-9-CM code (7th medication reported)	See note
	5	493.9-786.09	
	64	888888 Blank but applicable	
	13875	Blank	
288-292 HYK12SM		For how long has -- been taking or using (MEDICINE)? (days) (7th medication reported)	See note
	6	00182-04015	

	63	88888 Blank but applicable	
	13875	Blank	
293-296 HYK9DN		Primary drug class code (8th medication reported)	See note
	3	0916-1940	
	63	8888 Blank but applicable	
	13878	Blank	
297-300 HYK9EN		Secondary drug class code (8th medication reported)	See note
	66	8888 Blank but applicable	
	13878	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
301-304 HYK9FN		Tertiary drug class code (8th medication reported)	See note
	66	8888 Blank but applicable	
	13878	Blank	
305-310 HYK11AN		ICD-9-CM code (8th medication reported)	See note
	3	493.9-593.9	
	63	888888 Blank but applicable	
	13878	Blank	
311-315 HYK12SN		For how long has -- been taking or using (MEDICINE)? (days) (8th medication reported)	See note
	3	02190-04015	
	63	88888 Blank but applicable	
	13878	Blank	
316-319 HYK9DO		Primary drug class code (9th medication reported)	See note
	1	1940	
	63	8888 Blank but applicable	
	13880	Blank	
320-323 HYK9EO		Secondary drug class code (9th medication reported)	See note
	64	8888 Blank but applicable	

	13880	Blank	
324-327 HYK9FO		Tertiary drug class code (9th medication reported)	See note
	64	8888 Blank but applicable	
	13880	Blank	
328-333 HYK11AO		ICD-9-CM code (9th medication reported)	See note
	1	493.9	
	63	888888 Blank but applicable	
	13880	Blank	

NHANES III Partial Household Youth Data File

HOUSEHOLD YOUTH QUESTIONNAIRE (HYQ)

SECTION K. VITAMIN, MINERAL, AND MEDICINE USAGE

Positions SAS name	Counts	Item description and code	Notes
334-338 HYK12SO		For how long has -- been taking or using (MEDICINE)? (days) (9th medication reported)	See note
	1	02190	
	63	88888 Blank but applicable	
	13880	Blank	

Notes:

HYK1A: Has -- taken any vitamins or minerals in the past month?

This was the lead-in question for a series of questions on vitamins and minerals. If the response to this question was yes, the respondent or proxy was asked the number of supplements they took. For each supplement taken the respondent was asked about how often the supplement was taken, the dosage, and duration of use. The user should be aware, however, that there were respondents who reported taking supplements, but did not answer some or all of the remaining questions about the supplements. Although this lead-in question was designed to determine whether the respondent was using any vitamin or mineral supplements, respondents often reported taking other types of dietary supplements such as formula diets, sports drinks, herbs, plants and similar products, amino acids, bee pollen, lipotropics, fish oils, and enzymes. This information was retained along with the vitamin/mineral supplements. However, since the question did not ask specifically about the use of other nonvitamin/nonmineral dietary

supplements, the frequency with which these products were reported should not be considered to be nationally representative. It should also be noted that all of the information from the section does not appear in this data file; additional variables including supplement formulations will be released as a separate data file.

HYK1B: Has -- taken or used any prescription medicines in the past month?

This was the lead-in question for a series of questions on prescription medicines. If the response to this question was yes, the respondent or proxy was asked the number of prescription medicines they took. For each prescription medicine taken the respondent was asked to describe the health problem for which they took the medicine, and how long they had been taking the medicine. The user should be aware, however, that there were respondents who reported taking prescription medicines, but were only able to answer some of the remaining prescription drug questions. Prescribed vitamin or mineral supplements (e.g., fluoride, iron, and prenatal vitamins) originally reported as prescription drugs were moved to the vitamin/mineral section. These could, in fact, be considered either a drug or a supplement such as calcium-based antacid, calcitrol, and potassium. It should also be noted that all of the information from the section does not appear in this data file; additional variables including drug formulations will be released as a separate data file.

HYK2A: Number of vitamins/mineral supplements reported

This variable represents the total number of different supplements reported by the respondent or proxy. For each supplement reported, the interviewer asked to see the supplement container in order to record the name of the product and the manufacturer. If the container was not available, the interviewer probed for this information. Supplements that appear to be identical or duplications of another reported product are usually different forms (e.g., tablet vs. liquid) of the same product.

HYK2B: Number of prescription drugs reported

This variable represents the total number of different prescription medicines reported by the respondent or proxy. For each medication reported, the interviewer asked to see the medication container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Reports of non-prescription drug use, such as antacids, were deleted. However, calcium-containing antacids were moved to the vitamin/mineral supplements section. Medicines that appear to be identical or duplications of another reported product are usually different forms (e.g., tablet vs. liquid) of the same product.

HYK3CG, HYK3CH, HYK3CI, HYK3CJ, HYK3CK, HYK3CL, HYK3CM, HYK3CN, HYK3CO, HYK3CP:

Certainty index codes

A certainty index was derived as a means of evaluating how closely the reported name of a dietary supplement matched a standard or brand name

product which, in turn, was used for determining nutrient intakes. Each reported dietary supplement was assigned a certainty code. The index consists of six levels ranging from the highest degree of certainty that the reported supplement was correctly identified (code=1) to no level the lowest degree of certainty (code=6) , i.e., no match could be made between the reported supplement and a standard supplement. More specifically, the code of 1 was used when the respondent provided enough information about the product that it exactly matched a specific brand name supplement. A code of 2 was applied when the product name was partially incomplete or misspelled, but generally identifiable. A code of 3 was used for cases where a single nutrient supplement, such as calcium, was reported without the concentration. A code of 4 was applied when a generic type of supplement was reported such as "children's chewable multivitamins" or "iron vitamins" when it was not possible to identify the specific brand name or nutrient composition. A code of 5 was assigned to supplements that could not be readily identified although they were thought to be dietary supplements such as "Shaklee vitamins" or "Diamite nutritional". A code of 6 was used for products that could not be identified.

HYK3DG, HYK3DH, HYK3DI, HYK3DJ, HYK3DK, HYK3DL, HYK3DM, HYK3DN, HYK3DO, HYK3DP:
Product class

Each reported dietary supplement was categorized into one of 7 broad product-type classes according to general nutrient composition. The first five classes (1-5) were assigned only to vitamin and/or mineral supplements. The remaining two classes (6 and 7) were assigned to other dietary supplements including amino acids, lipotropics, herbs, plants and other nontraditional dietary supplements. Dietary supplements that also contained a vitamin and/or a mineral (e.g., ginseng and bee pollen with vitamin E) were assigned to class 6, whereas those that did not include vitamins or minerals were assigned to class 7.

HYK6SG, HYK6SH, HYK6SI, HYK6SJ, HYK6SK, HYK6SL, HYK6SM, HYK6SN, HYK6SO, HYK6SP:

How often did -- take -- in the past month?

These variables were created for each reported dietary supplement from the two-part (number and unit) question K6, and indicate how frequently each supplement was taken in the past month. The conversion factors used for days and weeks were 30 and 4, respectively. While frequency of use was standardized to "month," new supplement users may have been taking the supplement for less a month at the time of the interview. Analysts, therefore, may want to examine duration (HYK8S variables) as well as frequency of use.

HYK8SG, HYK8SH, HYK8SI, HYK8SJ, HYK8SK, HYK8SL, HYK8SM, HYK8SN, HYK8SO, HYK8SP:

How long has -- been taking this product? (months)

This variable was created from the two-part (number and unit) question K8, and indicates the long-term duration of use. The conversion factor was 12 months/year. When supplements were reported as prescription drugs and then moved as part of the data editing process (see note for variable

HK1A) much of the information was not directly transferable. For example, categories for duration of taking drugs (HYK12S variables) did not always match those listed for the corresponding question for vitamin/mineral supplements (HYK8S variables). Responses reported in weeks were rounded to the nearest month, whereas response in months and years were transferred directly.

HYK9DG, HYK9DH, HYK9DI, HYK9DJ, HYK9DK, HYK9DL, HYK9DM, HYK9DN, HYK9DO:
Primary drug class code

Up to three drug class codes were assigned for each reported prescription medication. These 4-digit codes were supplied by the Product Information Branch, Center for Drug Evaluation and Research at the U.S. DDHS Food and Drug Administration. The version of these codes that was used was last updated in October 1994. The primary drug class code assignment was based on the known drug action. For example, all cardiovascular drugs that were beta-adrenergic blocking agents were assigned the drug class code 0512 (beta blockers). See Appendix 2 for listing of codes.

HYK9EG, HYK9EH, HYK9EI, HYK9EJ, HYK9EK, HYK9EL, HYK9EM, HYK9EN, HYK9EO:
Secondary drug class code

This variable contains the second drug class codes for each prescription drug reported. If medical condition for which the medication was used (as reported in question K11) was different than the known drug action, then a secondary drug class code was entered. For example, a cardiovascular drug that was a beta-adrenergic blocking agent was assigned the drug class code 0512 (beta blocker) as the primary drug code, and a secondary drug class of 0502 (antiarrhythmic). If the reason provided did not relate to any of the known actions of the drug, then only the medication-specific (primary) class code was assigned. See Appendix 2 for listing of codes.

HYK9FG, HYK9FH, HYK9FI, HYK9FJ, HYK9FK, HYK9FL, HYK9FM, HYK9FN, HYK9FO:
Tertiary drug class code

This variable contains the tertiary drug class codes for each prescription drug reported. If medical condition for which the medication was used (as reported in question K11) was different than the primary drug class, then a secondary, and tertiary drug class code was entered. For example, a cardiovascular drug was assigned the drug class code 0512 (beta blocker) as the primary drug code, a secondary drug class code of 0502 (antiarrhythmics), and a tertiary code of 0506 (antihypertensives). If the reason provided did not relate to any of the actions of the drug, then only the medication-specific class code (primary) was assigned. See Appendix 2 for listing of codes.

HYK11AG, HYK11AH, HYK11AI, HYK11AJ, HYK11AK, HYK11AL, HYK11AM, HYK11AN,
HYK11AO:

ICD-9-CM code

ICD-9-CM codes were used to classify the medical conditions reported in question K11 for each prescription drug reported. Conditions were coded

to the fourth digit ICD-9-CM level of specificity except in those cases where the three digit ICD-9-CM code is the highest level of specificity. Some conditions where no appropriate code was available in the Classification of Diseases and Injuries ICD-9-CM codes, were coded using V Codes - Supplementary Classification of factors Influencing Health Status and Contact with Health Services. See Appendix 3 for listing of codes.

HYK12SG, HYK12SH, HYK12SI, HYK12SJ, HYK12SK, HYK12SL, HYK12SM, HYK12SN, HYK12SO:

For how long have -- been taking this medicine? (days)

This variable was created from the two-part (number and unit) question K12 (standardized in days). The conversion factors for weeks, months, and years were 7, 30, and 365, respectively. For medicines originally reported as supplements and moved in the data editing process, duration of use could not always be directly transferred. The categories for duration of supplement use in question K8 did not match those listed for the corresponding question under prescription medicines (K12). A response of "less than one month" in K8 was changed to blank but applicable (8-fills) in K12 for medicines that were originally recorded as supplements.

Appendix 1

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0002	ACEBUTOLOL HYDROCHLORIDE
0020	ACETAMINOPHEN; BUTALBITAL
0021	ACETAMINOPHEN; BUTALBITAL; CAFFEINE
0022	ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0046	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0048	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE
0050	ACETAMINOPHEN; CHLORZOXAZONE
0051	ACETAMINOPHEN; CODEINE PHOSPHATE

0064	ACETAMINOPHEN; DICHLORALPHENAZONE; ISOMETHEPTENE MUCATE
0070	ACETAMINOPHEN; HYDROCODONE BITARTRATE
0072	ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
0074	ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
0081	ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
0082	ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
0084	ACETAMINOPHEN; SALICYLAMIDE
0086	ACETAZOLAMIDE
0087	ACETIC ACID
0088	ACETIC ACID; HYDROCORTISONE
0092	ACETOHEXAMIDE
0105	ACYCLOVIR
0115	ALBUTEROL
0116	ALCLOMETASONE DIPROPIONATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0133	ALLOPURINOL
0140	ALPRAZOLAM
0154	ALUMINUM CHLORIDE HEXAHYDRATE
0174	AMANTADINE HYDROCHLORIDE
0176	AMCINONIDE
0179	AMILORIDE HYDROCHLORIDE
0180	AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
0207	AMINOPHYLLINE
0212	AMIODARONE HYDROCHLORIDE
0213	AMITRIPTYLINE HYDROCHLORIDE

0214	AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE
0215	AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
0230	AMOXAPINE
0231	AMOXICILLIN
0232	AMOXICILLIN; CLAVULANATE POTASSIUM
0239	AMPICILLIN/AMPICILLIN TRIHYDRATE
0244	AMYLASE; CELLULASE; LIPASE; PROTEASE
0254	ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
0255	ANTHRALIN
0260	ANTIHEMOPHILIC FACTOR, HUMAN
0263	ANTIPYRINE; BENZOCAINE
0264	ANTIPYRINE; BENZOCAINE; PHENYLEPHRINE HYDROCHLORIDE
0276	APRACLONIDINE HYDROCHLORIDE
0299	ASPIRIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0302	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0304	ASPIRIN; BUTALBITAL; CAFFEINE
0306	ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
0310	ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
0311	ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
0314	ASPIRIN; CARISOPRODOL
0315	ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
0317	ASPIRIN; CODEINE PHOSPHATE
0320	ASPIRIN; MEPROBAMATE

0321	ASPIRIN; METHOCARBAMOL
0322	ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
0332	ASTEMIZOLE
0333	ATENOLOL
0334	ATENOLOL; CHLORTHALIDONE
0336	ATROPINE SULFATE
0338	ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
0339	ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
0340	ATROPINE SULFATE; BENZOIC ACID; HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE
0347	AURANOFIN
0349	AZATADINE MALEATE
0350	AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
0351	AZATHIOPRINE
0356	BACITRACIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0357	BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
0358	BACITRACIN ZINC; POLYMYXIN B SULFATE
0361	BACLOFEN
0376	BECLOMETHASONE DIPROPIONATE
0380	BELLADONNA; CAFFEINE; ERGOTAMINE; PENTOBARBITAL
0382	BELLADONNA
0383	BELLADONNA ALKALOIDS; PHENOBARBITAL
0389	BELLADONNA; ENZYME(S); PHENOBARBITAL
0391	BELLADONNA; KAOLIN; PAREGORIC; PECTIN

0403	BENDROFLUMETHIAZIDE; NADOLOL
0417	BENZOCAINE
0446	BENZONATATE
0447	BENZOYL PEROXIDE
0448	BENZOYL PEROXIDE; ERYTHROMYCIN
0455	BENZTROPINE MESYLATE
0462	BETAMETHASONE
0465	BETAMETHASONE DIPROPIONATE
0466	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
0468	BETAMETHASONE VALERATE
0469	BETAXOLOL HYDROCHLORIDE
0470	BETHANECHOL CHLORIDE
0476	BILE SALTS; PANCREATIN; PEPSIN
0505	BITOLTEROL MESYLATE
0527	BROMOCRIPTINE MESYLATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0528	BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
0529	BROMPHENIRAMINE MALEATE
0530	BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0531	BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
0532	BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0533	BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0534	BROMPHENIRAMINE; DEXTROMETHORPHAN; PHENYLPROPANOLAMINE

0538	BROMPHENIRAMINE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLTOLOXAMINE
0544	BUMETANIDE
0550	BUPROPION HYDROCHLORIDE
0551	BUSPIRONE HYDROCHLORIDE
0557	BUTABARBITAL SODIUM
0574	CAFFEINE; ERGOTAMINE TARTRATE
0585	CALCITONIN, SALMON
0586	CALCITRIOL
0607	CALCIUM IODIDE; CODEINE PHOSPHATE
0642	CAPTOPRIL
0643	CAPTOPRIL; HYDROCHLOROTHIAZIDE
0644	CARAMIPHEN; PHENYLPROPANOLAMINE
0645	CARBACHOL
0646	CARBAMAZEPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0652	CARBETAPENTANE TANNATE; CHLORPHENIRAMINE TANNATE; EPHEDRINE TANNATE; PHENYLEPHRINE HYDROCHLORIDE
0653	CARBIDOPA; LEVODOPA
0655	CARBINOXAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
0656	CARBINOXAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0664	CARISOPRODOL
0666	CARTEOLOL HYDROCHLORIDE
0680	CEFACLOR
0681	CEFADROXIL
0684	CEFIXIME

0687	CEFOPERAZONE SODIUM
0694	CEFTRIAZONE SODIUM
0695	CEFUROXIME AXETIL
0698	CEPHALEXIN
0699	CEPHALEXIN HYDROCHLORIDE
0702	CEPHRADINE
0726	CHLORDIAZEPOXIDE HYDROCHLORIDE
0727	CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE
0728	CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED
0729	CHLORHEXIDINE GLUCONATE
0738	CHLOROQUINE PHOSPHATE
0739	CHLOROTHIAZIDE
0740	CHLOROTHIAZIDE; METHYLDOPA
0741	CHLOROTHIAZIDE; RESERPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0743	CHLOROXINE
0749	CHLORPHENIRAMINE MALEATE; HYDROCODONE; PHENYLEPHRINE HYDROCHLORIDE
0751	CHLORPHENIRAMINE MALEATE
0753	CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0754	CHLORPHENIRAMINE MALEATE; EPINEPHRINE
0755	CHLORPHENIRAMINE MALEATE; METHSCOPOLAMINE NITRATE; PHENYLEPHRINE HYDROCHLORIDE
0756	CHLORPHENIRAMINE MALEATE; PHENINDAMINE TARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0757	CHLORPHENIRAMINE MALEATE;

	PHENYLEPHRINE HYDROCHLORIDE; PHENYLTOLOXAMINE CITRATE
0758	CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0759	CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
0760	CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
0761	CHLORPHENIRAMINE TANNATE; PHENYLEPHRINE TANNATE; PYRILAMINE TANNATE
0767	CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; POTASSIUM IODIDE
0775	CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
0776	BECLOMETHASONE DIPROPIONATE
0790	CHLORPHENIRAMINE MALEATE; HYDROCODONE; PSEUDOEPHEDRINE
0792	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0793	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PYRILAMINE
0797	CHLORPROMAZINE HYDROCHLORIDE
0798	CHLORPROPAMIDE
0801	CHLORTHALIDONE
0802	CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
0803	CHLORTHALIDONE; RESERPINE
0804	CHLORZOAZONE
0808	CHOLESTYRAMINE
0811	CHOLINE MAGNESIUM TRISALICYLATE

0817	CICLOPIROX OLAMINE
0820	CIMETIDINE
0823	CIPROFLOXACIN HYDROCHLORIDE
0830	CITRIC ACID; SODIUM CITRATE
0835	CLEMASTINE FUMARATE
0836	CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0838	CLINDAMYCIN HYDROCHLORIDE
0839	CLOBETASOL PROPIONATE
0842	CLOFIBRATE
0843	CLOMIPHENE CITRATE
0845	CLONAZEPAM
0846	CLONIDINE HYDROCHLORIDE
0847	CLORAZEPATE DIPOTASSIUM
0848	CLOTRIMAZOLE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0850	CLOXACILLIN SODIUM
0851	CLOZAPINE
0870	CODEINE PHOSPHATE
0873	CODEINE PHOSPHATE; GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
0874	CODEINE PHOSPHATE; IODINATED GLYCEROL
0875	CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
0876	CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
0878	CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
0881	CODEINE PHOSPHATE; GUAIFENESIN

0883	CODEINE PHOSPHATE; GUAIFENESIN; PHENYLPROPANOLAMINE
0890	COLCHICINE
0891	COLCHICINE; PROBENECID
0892	COLESTIPOL HYDROCHLORIDE
0894	COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
0907	CORTISONE ACETATE
0916	CROMOLYN SODIUM
0924	CYCLANDELATE
0926	CYCLOBENZAPRINE HYDROCHLORIDE
0930	CYCLOPHOSPHAMIDE
0932	CYCLOSPORINE
0934	CYPROHEPTADINE HYDROCHLORIDE
0940	DANAZOL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0944	DANTROLENE SODIUM
0947	DEFEROXAMINE MESYLATE
0951	DEHYDROCHOLIC ACID
0963	DESERPIDINE; METHYCLOTHIAZIDE
0964	DESIPRAMINE HYDROCHLORIDE
0966	DESMOPRESSIN ACETATE
0967	DESONIDE
0968	DESOXIMETASONE
0974	DEXAMETHASONE
0976	DEXAMETHASONE SODIUM PHOSPHATE

0978	DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
0979	DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
0980	DEXAMETHASONE; TOBRAMYCIN
0982	DEXBROMPHENIRAMINE; PSEUDOEPHEDRINE
0983	DEXCHLORPHENIRAMINE MALEATE
0987	DEXTRAN
0992	DEXTROAMPHETAMINE SULFATE
0994	DEXTROMETHORPHAN HYDROBROMIDE; IODINATED GLYCEROL
0995	DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
1000	DEXTROMETHORPHAN; GUAIFENESIN
1033	DIAZEPAM
1044	DICHLORPHENAMIDE
1045	DICLOFENAC SODIUM
1046	DICLOXACILLIN SODIUM

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1048	DICYCLOMINE HYDROCHLORIDE
1050	DIENESTROL
1053	DIETHYLPROPION HYDROCHLORIDE
1054	DIETHYLSTILBESTROL
1055	DIETHYLSTILBESTROL DIPHOSPHATE
1057	DIFLORASONE DIACETATE
1058	DIFLUNISAL
1060	DIGITOXIN
1061	DIGOXIN
1063	DIHYDROERGOTAMINE MESYLATE

1065	DIHYDROTACHYSTEROL
1068	HYDROCORTISONE; IODOQUINOL
1069	DILTIAZEM HYDROCHLORIDE
1070	DIMENHYDRINATE
1079	DIPHENHYDRAMINE HYDROCHLORIDE
1088	DIPIVEFRIN HYDROCHLORIDE
1090	DIPYRIDAMOLE
1093	DISOPYRAMIDE PHOSPHATE
1096	DIVALPROEX SODIUM
1111	DOXEPIN HYDROCHLORIDE
1113	DOXYCYCLINE
1122	DYPHYLLINE
1124	DYPHYLLINE; GUAIFENESIN
1126	ECHOTHIOPHATE IODIDE
1127	ECONAZOLE NITRATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1138	ENALAPRIL MALEATE
1139	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
1141	ENCAINIDE HYDROCHLORIDE
1145	ENZYME(S); HYOSCYAMINE SULFATE; PHENYLTOLOXAMINE CITRATE
1149	EPHEDRINE
1151	EPHEDRINE HYDROCHLORIDE; PHENOBARBITAL; THEOPHYLLINE ANHYDROUS
1152	EPHEDRINE SULFATE; HYDROXYZINE HYDROCHLORIDE; THEOPHYLLINE
1160	EPHEDRINE HYDROCHLORIDE; POTASSIUM IODIDE; PHENOBARBITAL; THEOPHYLLINE

1166	EPINEPHRINE
1169	EPINEPHRYL BORATE
1172	EPINEPHRINE; PILOCARPINE
1173	EPOETIN ALFA
1174	ERGOCALCIFEROL
1175	ERGOLOID MESYLATES
1177	ERGOTAMINE TARTRATE
1178	ERYTHRITYL TETRANITRATE
1179	ERYTHROMYCIN
1180	ERYTHROMYCIN ESTOLATE
1181	ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL
1182	ERYTHROMYCIN ETHYLSUCCINATE
1184	ERYTHROMYCIN LACTOBIONATE
1185	ERYTHROMYCIN STEARATE
1188	ESTRADIOL

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1191	ESTRADIOL VALERATE
1195	ESTRAMUSTINE PHOSPHATE SODIUM
1196	ESTROGENIC SUBSTANCES
1197	ESTROGENS, CONJUGATED
1200	ESTROGENS, ESTERIFIED
1201	ESTROGENS, ESTERIFIED; METHYLTESTOSTERONE
1204	ESTROPIPATE
1206	ETHAMBUTOL HYDROCHLORIDE
1208	ETHAVERINE HYDROCHLORIDE
1213	ETHCHLORVYNOL

1216	ETHINYL ESTRADIOL
1217	ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
1219	ETHINYL ESTRADIOL; LEVONORGESTREL
1220	ETHINYL ESTRADIOL; NORETHINDRONE
1221	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE; FERROUS FUMARATE
1222	ETHINYL ESTRADIOL; NORGESTREL
1226	ETHOSUXIMIDE
1234	ETIDRONATE DISODIUM
1237	ETRETINATE
1246	FAMOTIDINE
1253	FENOPROFEN CALCIUM
1297	FLAVOXATE HYDROCHLORIDE
1299	FLECAINIDE ACETATE
1301	FLUCONAZOLE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1303	FLUDROCORTISONE ACETATE
1305	FLUNISOLIDE
1306	FLUOCINOLONE ACETONIDE
1310	FLUOCINONIDE
1317	FLUROMETHOLONE
1319	FLUOROURACIL
1320	FLUOXETINE HYDROCHLORIDE
1321	FLUOXYMESTERONE
1322	FLUPHENAZINE DECANOATE
1324	FLUPHENAZINE HYDROCHLORIDE

1325	FLURANDRENOLIDE
1327	FLURAZEPAM HYDROCHLORIDE
1328	FLURBIPROFEN
1330	FLUTAMIDE
1331	FOLIC ACID
1342	FUROSEMIDE
1351	GEMFIBROZIL
1352	GENTAMICIN SULFATE
1353	GENTAMICIN SULFATE; PREDNISOLONE ACETATE
1357	GLIPIZIDE
1366	GLUTETHIMIDE
1368	GLYBURIDE
1377	GLYCOPYRROLATE
1379	GOLD SODIUM THIOMALATE
1382	GOSERELIN ACETATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1385	GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1388	GRISEOFULVIN, MICROCRYSTALLINE
1389	GRISEOFULVIN, ULTRAMICROCRYSTALLINE
1391	GUAIFENESIN
1395	GUAIFENESIN; HYDROCODONE BITARTRATE
1402	GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
1403	GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE
1404	GUAIFENESIN; PHENYLPROPANOLAMINE HYDROCHLORIDE
1405	GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
1406	GUAIFENESIN; PSEUDOEPHEDRINE; THEOPHYLLINE

1407	GUAIFENESIN; THEOPHYLLINE
1408	GUANABENZ ACETATE
1410	GUANETHIDINE MONOSULFATE
1412	GUANFACINE HYDROCHLORIDE
1418	HALOPERIDOL
1419	HALOPERIDOL DECANOATE
1427	HEPARIN LOCK FLUSH
1436	HEXACHLOROPHENE
1440	HISTAMINE PHOSPHATE
1444	HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
1450	HYDRALAZINE HYDROCHLORIDE
1451	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
1452	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
1456	HYDROCHLOROTHIAZIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1457	HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE
1458	HYDROCHLOROTHIAZIDE; LISINOPRIL
1459	HYDROCHLOROTHIAZIDE; METHYLDOPA
1460	HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
1461	HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
1462	HYDROCHLOROTHIAZIDE; RESERPINE
1463	HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
1464	HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE
1465	HYDROCHLOROTHIAZIDE; TRIAMTERENE
1468	HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE;

	PHENYLPROPANOLAMINE HYDROCHLORIDE; PYRILAMINE
1469	HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
1470	HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
1476	HYDROCORTISONE
1477	HYDROCORTISONE ACETATE
1480	HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE
1482	HYDROCORTISONE BUTYRATE
1483	HYDROCORTISONE CYPIONATE
1485	HYDROCORTISONE SODIUM SUCCINATE
1486	HYDROCORTISONE VALERATE
1490	HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1496	HYDROFLUMETHIAZIDE
1497	HYDROFLUMETHIAZIDE; RESERPINE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1500	HYDROMORPHONE HYDROCHLORIDE
1506	HYDROXYCHLOROQUINE SULFATE
1512	HYDROXYUREA
1513	HYDROXYZINE HYDROCHLORIDE
1514	HYDROXYZINE PAMOATE
1516	HYOSCYAMINE SULFATE
1517	HYOSCYAMINE SULFATE; PHENOBARBITAL
1520	IBUPROFEN
1525	IMIPRAMINE HYDROCHLORIDE
1526	IMIPRAMINE PAMOATE

1529	INDAPAMIDE
1532	INDOMETHACIN
1546	INTERFERON ALFA-2B, RECOMBINANT
1555	IODINATED GLYCEROL
1556	IODINATED GLYCEROL; THEOPHYLLINE
1557	IODINE
1578	IPRATROPIUM BROMIDE
1581	ISOCARBOXAZID
1583	ISOETHARINE MESYLATE
1585	ISONIAZID
1587	ISONIAZID; RIFAMPIN
1590	ISOPROTERENOL HYDROCHLORIDE
1592	ISOSORBIDE
1593	ISOSORBIDE DINITRATE
1595	ISOTRETINOIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1596	ISOXSUPRINE HYDROCHLORIDE
1605	KETOCONAZOLE
1606	KETOPROFEN
1607	KETOROLAC TROMETHAMINE
1612	LEVOTHYROXINE SODIUM
1613	LABETALOL HYDROCHLORIDE
1621	LACTULOSE
1630	LEUCOVORIN CALCIUM
1631	LEUPROLIDE ACETATE
1632	LEVAMISOLE HYDROCHLORIDE

1633	LEVOBUNOLOL HYDROCHLORIDE
1634	LEVOCARNITINE
1635	LEVODOPA
1638	LIDOCAINE
1639	LIDOCAINE HYDROCHLORIDE
1641	LINCOMYCIN HYDROCHLORIDE
1642	LINDANE
1645	LIOTHYRONINE SODIUM
1646	LIOTRIX (T4,T3)
1647	LISINOPRIL
1648	LITHIUM CARBONATE
1660	LOMUSTINE
1661	LOPERAMIDE HYDROCHLORIDE
1662	LORAZEPAM
1664	LOVASTATIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1666	LOXAPINE SUCCINATE
1677	MAGALDRATE; SIMETHICONE
1695	MANGANESE
1705	MEBENDAZOLE
1708	MECLIZINE HYDROCHLORIDE
1710	MECLOFENAMATE SODIUM
1712	MEDROXYPROGESTERONE ACETATE
1713	MEDRYSONE
1714	MEFENAMIC ACID
1716	MEGESTROL ACETATE

1726	MEPENZOLATE BROMIDE
1727	MEPERIDINE HYDROCHLORIDE
1728	MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
1731	MEPHOBARBITAL
1734	MEPROBAMATE
1737	MERCAPTOPYRINE
1742	MESALAMINE
1744	MESORIDAZINE BESYLATE
1747	METAPROTERENOL SULFATE
1749	METAXALONE
1753	METHADONE HYDROCHLORIDE
1759	METHAZOLAMIDE
1761	METHENAMINE HIPPURATE
1762	METHENAMINE MANDELATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1765	METHIMAZOLE
1767	METHIONINE; SODIUM PROPIONATE; UREA
1768	METHOCARBAMOL
1770	METHOTREXATE SODIUM
1777	METHSUXIMIDE
1778	METHYCLOTHIAZIDE
1780	METHYCLOTHIAZIDE; RESERPINE
1787	METHYLDOPA
1789	METHYLERGONOVINE MALEATE
1790	METHYLPHENIDATE HYDROCHLORIDE

1791	METHYLPREDNISOLONE
1795	METHYLTESTOSTERONE
1798	METOCLOPRAMIDE HYDROCHLORIDE
1800	METOLAZONE
1801	METOPROLOL TARTRATE
1803	METRONIDAZOLE
1806	MEXILETINE HYDROCHLORIDE
1809	MICONAZOLE NITRATE
1818	MINOCYCLINE HYDROCHLORIDE
1819	MINOXIDIL
1820	MISOPROSTOL
1826	MOLINDONE HYDROCHLORIDE
1828	MOMETASONE FUROATE
1833	MORPHINE SULFATE
1843	MUPIROCIN

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1849	NADOLOL
1856	NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
1858	NANDROLONE DECANOATE
1860	NAPHAZOLINE HYDROCHLORIDE
1861	NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE
1864	NAPROXEN
1865	NAPROXEN SODIUM
1868	NEOMYCIN SULFATE
1869	NEOMYCIN SULFATE; POLYMYXIN B SULFATE

1870	NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
1876	NIACIN
1882	NICARDIPINE HYDROCHLORIDE
1884	NICOTINE POLACRILEX
1886	NIFEDIPINE
1890	NITROFURANTOIN
1891	NITROFURANTOIN, MACROCRYSTALLINE
1893	NITROGLYCERIN
1894	NIZATIDINE
1900	NORETHINDRONE ACETATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1901	NORFLOXACIN
1903	NORTRIPTYLINE HYDROCHLORIDE
1907	NYLIDRIN HYDROCHLORIDE
1908	NYSTATIN
1909	NYSTATIN; TRIAMCINOLONE ACETONIDE
1916	OMEPRAZOLE
1920	ORPHENADRINE CITRATE
1923	OXACILLIN SODIUM
1926	OXAZEPAM
1927	OXICONAZOLE NITRATE
1929	OXTRIPHYLLINE
1930	OXYBUTYNYNIN CHLORIDE
1932	OXYCODONE HYDROCHLORIDE
1948	PANCREATIN

1949	PANCRELIPASE
1953	PAPAVERINE HYDROCHLORIDE
1960	PAREGORIC
1963	PEMOLINE
1964	PENBUTOLOL SULFATE
1965	PENICILLAMINE
1968	PENICILLIN G POTASSIUM
1971	PENICILLIN V POTASSIUM
1972	PENTAERYTHRITOL TETRANITRATE
1977	PENTAZOCINE LACTATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
1980	PENTOXIFYLLINE
1986	PERGOLIDE MESYLATE
1988	PERPHENAZINE
1995	PHENAZOPYRIDINE HYDROCHLORIDE
1996	PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE
1998	PHENDIMETRAZINE TARTRATE
1999	PHENELZINE SULFATE
2002	PHENIRAMINE; PHENYLPROPANOLAMINE; PYRILAMINE
2003	PHENIRAMINE; PHENYLTOLOXAMINE; PYRILAMINE
2005	PHENOBARBITAL
2013	PHENOXYBENZAMINE HYDROCHLORIDE
2016	PHENTERMINE HYDROCHLORIDE
2019	PHENYLBUTAZONE
2020	PHENYLEPHRINE HYDROCHLORIDE
2021	PHENYLEPHRINE HYDROCHLORIDE;

	PROMETHAZINE HYDROCHLORIDE
2027	PHENYLPROPANOLAMINE HYDROCHLORIDE
2029	PHENYTOIN
2030	PHENYTOIN SODIUM
2035	PHYTONADIONE
2036	PILOCARPINE HYDROCHLORIDE
2038	PIMOZIDE
2039	PINDOLOL
2046	PIRBUTEROL ACETATE
2047	PIROXICAM

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2069	POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE
2070	POLYTHIAZIDE; RESERPINE
2073	POTASSIUM
2078	POTASSIUM BICARBONATE
2081	POTASSIUM CHLORIDE
2084	POTASSIUM GLUCONATE
2085	POTASSIUM IODIDE
2086	POTASSIUM IODIDE; THEOPHYLLINE ANHYDROUS
2098	PRAZEPAM
2100	PRAZOSIN HYDROCHLORIDE
2102	PREDNISOLONE
2103	PREDNISOLONE ACETATE
2104	PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
2105	PREDNISOLONE SODIUM PHOSPHATE
2106	PREDNISOLONE SODIUM PHOSPHATE;

	SULFACETAMIDE SODIUM
2109	PREDNISONE
2114	PRIMIDONE
2115	PROBENECID
2116	PROBUCOL
2117	PROCAINAMIDE HYDROCHLORIDE
2118	PROCAINE HYDROCHLORIDE
2120	PROCHLORPERAZINE
2122	PROGESTERONE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2125	PROMETHAZINE HYDROCHLORIDE
2127	PROPAFENONE HYDROCHLORIDE
2128	PROPANTHELINE BROMIDE
2133	PROPOXYPHENE HYDROCHLORIDE
2134	PROPOXYPHENE NAPSYLATE
2135	PROPRANOLOL HYDROCHLORIDE
2138	PROPYLTHIOURACIL
2143	PROTRIPTYLINE HYDROCHLORIDE
2144	PSEUDOEPHEDRINE HYDROCHLORIDE
2145	PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
2150	PYRAZINAMIDE
2151	PYRIDOSTIGMINE BROMIDE
2152	PYRIDOXINE HYDROCHLORIDE
2156	PYRIMETHAMINE; SULFADOXINE
2160	QUAZEPAM

2162	QUINESTROL
2165	QUINIDINE GLUCONATE
2166	QUINIDINE POLYGALACTURONATE
2167	QUINIDINE SULFATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2168	QUININE SULFATE
2174	RANITIDINE HYDROCHLORIDE
2176	RAUWOLFIA SERPENTINA
2179	RESERPINE
2188	RIFAMPIN
2203	SALICYLIC ACID
2206	SALSALATE
2218	SELEGILINE HYDROCHLORIDE
2220	SELENIUM SULFIDE
2241	SODIUM BICARBONATE
2243	SODIUM CHLORIDE
2244	SODIUM FLUORIDE
2258	SODIUM POLYSTYRENE SULFONATE
2260	SODIUM SULFACETAMIDE; SULFUR
2265	SOMATREM
2267	SORBITOL
2269	SPIRONOLACTONE
2270	STANNOUS FLUORIDE
2271	STANZOLOL
2280	SUCRALFATE
2282	SULCONAZOLE NITRATE

2283	SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE
2284	SULFACETAMIDE SODIUM
2287	SULFAMETHIZOLE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2288	SULFAMETHOXAZOLE
2289	SULFAMETHOXAZOLE; TRIMETHOPRIM
2291	SULFAPYRIDINE
2292	SULFASALAZINE
2293	SULFINPYRAZONE
2294	SULFISOXAZOLE
2298	SULINDAC
2306	TAMOXIFEN CITRATE
2310	TEMAZEPAM
2311	TERAZOSIN HYDROCHLORIDE
2312	TERBUTALINE SULFATE
2313	TERCONAZOLE
2314	TERFENADINE
2318	TESTOSTERONE
2319	TESTOSTERONE CYPIONATE
2326	TETRACYCLINE HYDROCHLORIDE
2329	THEOPHYLLINE
2341	THIORIDAZINE HYDROCHLORIDE
2343	THIOTHIXENE
2348	THYROGLOBULIN
2349	THYROID

2353	TIMOLOL MALEATE
2355	TOBRAMYCIN
2357	TOCAINIDE HYDROCHLORIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2358	TOLAZAMIDE
2360	TOLBUTAMIDE
2361	TOLMETIN SODIUM
2366	TRANYLCYPROMINE SULFATE
2367	TRAZODONE HYDROCHLORIDE
2368	TRETINOIN
2370	TRIAMCINOLONE
2371	TRIAMCINOLONE ACETONIDE
2374	TRIAMTERENE
2375	TRIAZOLAM
2376	TRICHLORMETHIAZIDE
2381	TRIETHANOLAMINE POLYPEPTIDE OLEATE CONDENSATE
2382	TRIFLUOPERAZINE HYDROCHLORIDE
2385	TRIHXYPHENIDYL HYDROCHLORIDE
2390	TRIMETHOBENZAMIDE HYDROCHLORIDE
2391	TRIMETHOPRIM
2394	TRIPLENNAMINE HYDROCHLORIDE
2396	TRIPROLIDINE HYDROCHLORIDE
2400	TROPICAMIDE
2418	URSODIOL
2419	VALPROIC ACID
2425	VERAPAMIL HYDROCHLORIDE

2444 WARFARIN SODIUM
2450 YOHIMBINE HYDROCHLORIDE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
2451	ZIDOVUDINE
3004	CALCIUM ACETATE
3007	DOXAZOSIN MESYLATE
3009	ESTAZOLAM
3012	HALOBETASOL PROPIONATE
3014	ISRADIPINE
3015	LEVONORGESTREL
3016	OFLOXACIN
3017	OLSALAZINE SODIUM
3022	METIPRANOLOL HYDROCHLORIDE
3024	PEGADEMASE BOVINE
3029	ETODOLAC
3031	ONDANSETRON HYDROCHLORIDE
3032	RAMIPRIL
3037	HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
3046	FILGRASTIM
3052	FOSINOPRIL SODIUM
3053	BENAZEPRIL HYDROCHLORIDE
3059	FELODIPINE
3060	DIDANOSINE
3062	PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE
3063	TICLOPIDINE HYDROCHLORIDE

3064 PRAVASTATIN SODIUM

3066 AZITHROMYCIN DIHYDRATE

Appendix 1 continued

Standardized Generic Prescription Medication Names

Rx Code Standard Generic Prescription Medication Name

3068 CLARITHROMYCIN

3069 QUINAPRIL HYDROCHLORIDE

3072 AMLODIPINE BESYLATE

3076 ZALCITABINE

3078 FINASTERIDE

3084 NEDOCROMIL SODIUM

3087 SERTRALINE HYDROCHLORIDE

3088 SIMVASTATIN

3089 SOTALOL HYDROCHLORIDE

3090 SUMATRIPTAN SUCCINATE

3091 TACRINE HYDROCHLORIDE

3102 CEFPROZIL

3106 ISOSORBIDE MONONITRATE

3107 LORACARBEF

3108 NABUMETONE

3109 NICOTINE

3110 NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

3126 CEFPODOXIME PROXETIL

3129 CLINDAMYCIN PHOSPHATE

3130 PAROXETINE HYDROCHLORIDE

3133 ITRACONAZOLE

3140 OXAPROZIN

3143	DESOGESTREL; ETHINYL ESTRADIOL
3145	ZOLPIDEM TARTRATE
3149	TERBINAFINE HYDROCHLORIDE
3156	SALMETEROL XINAFOATE
3161	LORATADINE
3164	CISAPRIDE MONOHYDRATE
3177	FLUOROMETHOLONE ACETATE
3179	TORSEMIDE
3182	RIMANTADINE HYDROCHLORIDE
7000	INSULIN
7500	KAOLIN; PAREGORIC; PECTIN
7501	HYDROCODONE BITARTRATE
7502	TIAPROFENIC ACID
7503	DIPHENOXYLATE HYDROCHLORIDE
0390	BELLADONNA; ERGOTAMINE; PHENOBARBITAL
1503	HYDROQUINONE
3184	LODOXAMIDE TROMETHAMINE

Appendix 2

CODE	DRUG CLASS DESCRIPTION
0100	ANESTHETICS
0117	ANESTHETICS, LOCAL
0118	ANESTHETICS, GENERAL
0119	ANESTHESIA, ADJUNCTS TO/ANAESTHETICS
0120	MEDICINAL GASES
0121	ANESTHETICS, TOPICAL
0122	ANESTHETICS, OPHTHALMIC
0123	ANESTHETICS, RECTAL
0200	ANTIDOTES
0281	ANTIDOTES, SPECIFIC
0283	ANTIDOTES, GENERAL
0285	ANTITOXINS/ANTIVENINS
0286	ANAPHYLAXIS TREATMENT KIT
0300	ANTIMICROBIALS
0346	PENICILLINS
0347	CEPHALOSPORINS
0348	LINCOSAMIDES/MACROLIDES

0349	POLYMYXINS
0350	TETRACYCLINE
0351	CHLORAMPHENICOL/DERIVATIVES
0352	AMINOGLYCOSIDES
0353	SULFONAMIDES/RELATED COMPOUNDS
0354	ANTISEPTICS, URINARY TRACT
0355	ANTIBACTERIALS, MISCELLANEOUS
0356	ANTIMYCOBACTERIALS (INCL ANTI LEPROSY)
0357	QUINOLONES/DERIVATIVES
0358	ANTIFUNGALS
0388	ANTIVIRALS
0400	HEMATOLOGICS
0408	DEFICIENCY ANEMIAS
0409	ANTICOAGULANTS/THROMBOLYTICS
0410	BLOOD COMPONENTS/SUBSTITUTES
0411	HEMOSTATICS
0500	CARDIOVASCULAR-RENAL
0501	CARDIAC GLYCOSIDES
0502	ANTIARRHYTHMICS
0503	ANTIANGINALS
0504	VASCULAR DISORDERS, CEREBRAL/PERIPHERAL
0505	HYPOTENSION/SHOCK
0506	ANTIHYPERTENSIVES
0507	DIURETICS
0508	CORONARY VASODILATORS
0509	RELAXANTS/STIMULANTS, URINARY TRACT
0510	CALCIUM CHANNEL BLOCKERS
0511	CARBONIC ANHYDRASE INHIBITORS
0512	BETA BLOCKERS
0513	ALPHA AGONISTS/ALPHA BLOCKERS
0514	ACE INHIBITORS
0600	CENTRAL NERVOUS SYSTEM

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
0626	SEDATIVES/HYPNOTICS
0627	ANTIANKXIETY
0628	ANTIPSYCHOTICS/ANTIMANICS
0630	ANTIDEPRESSANTS
0631	ANOREXIANTS/CNS STIMULANTS
0632	CNS, MISCELLANEOUS
0633	ALZHEIMER-TYPE DEMENTIA
0634	SLEEP AID PRODUCTS, PRIMARY OTC
0635	ANTIEMETICS
0700	CONTRAST MEDIA/ RADIOPHARMACEUTICALS
0789	DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
0790	DIAGNOSTICS RADIOPHARMACEUTICALS
0791	THERAPEUTICS RADIOPHARMACEUTICALS
0792	DIAGNOSTICS-MISC.
0800	GASTROINTESTINALS
0874	DISORDERS, ACID/PEPTIC
0875	ANTIDIARRHEALS

0876	LAXATIVES
0877	GASTROINTESTINAL, MISCELLANEOUS
0878	ANTISPASMODICS/ANTICHOLINERGICS
0879	ANTACIDS
0900	METABOLICS/NUTRIENTS
0912	HYPERLIPIDEMIA
0913	VITAMINS/MINERALS
0914	NUTRITION, ENTERAL/PARENTERAL
0915	REPL/REGS OF ELECTROLYTES/WATER BALANCE
0916	CALCIUM METABOLISM
0917	HEMATOPOIETICS
1000	HORMONES/HORMONAL MECHANISMS
1032	ADRENAL CORTICOSTEROIDS
1033	ADROGENS/ANABOLIC STEROIDS
1034	ESTROGENS/PROGESTINS
1035	ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION
1036	BLOOD GLUCOSE REGULATORS
1037	THYROID/ANTITHYROID
1038	ANTIDIURETICS
1039	RELAXANTS/STIMULANTS, UTERINE
1040	CONTRACEPTIVES
1041	INFERTILITY
1042	DISORDERS OF GROWTH HORMONE SECRETION
1100	IMMUNOLOGICS
1180	VACCINES/ANTISERA
1181	IMMUNOMODULATORS
1182	ALLERGENIC EXTRACTS
1183	IMMUNE SERUMS (INCLUDES IMMUNE GLOBULINS)
1200	SKIN/MUCOUS MEMBRANES
1264	ANTISEPTICS/DISINFECTANTS
1265	DERMATOLOGICS
1266	KERATOLYTICS

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1267	ANTIPERSPIRANTS
1268	TOPICAL STEROIDS
1269	BURN/SUNBURN, SUNSCREEN
1270	ACNE PRODUCTS
1271	TOPICAL ANTI-INFECTIVES
1272	ANORECTAL PRODUCTS
1273	PERSONAL CARE PRODUCTS
1274	DERMATITIS/ANTIPURETICS
1275	TOPICAL ANALGESICS
1300	NEUROLOGICS
1371	EXTRAPYRAMIDAL MOVEMENT DISORDERS
1372	MYASTHENIA GRAVIS
1373	SKELETAL MUSCLE HYPERACTIVITY
1374	ANTICONVULSANTS
1400	ONCOLYTICS
1479	ANTINEOPLASTICS
1480	ANTINEOPLASTICS-HORMONAL/BIOLOGICAL RESPONSE

1481	ANTINEOPLASTICS-ANTIMETABOLITES
1482	ANTINEOPLASTIC AGENTS
1483	ANTINEOPLASTICS-DNA DAMAGING AGENTS
1500	OPHTHALMICS
1566	GLAUCOMA
1567	CYCOPLEGICS/MYDRIATICS
1568	OCULAR ANTI-INFECTIVE/ANTI-INFLAMMATORY
1569	OPHTHALMICS, MISCELLANEOUS
1570	OPHTHALMICS-DECONGESTANTS/ANTI-ALLERGY AGENTS
1571	CONTACT LENS PRODUCTS
1600	OTICS
1670	OTICS, TOPICAL
1671	VERTIGO/MOTION SICKNESS/VOMITING
1700	RELIEF OF PAIN
1720	ANALGESICS, GENERAL
1721	ANALGESICS, NARCOTIC
1722	ANALGESICS, NON-NARCOTIC
1723	ANTIMIGRAINE/OTHER HEADACHES
1724	ANTIARTHRITICS
1725	ANTIGOUT
1726	CENTRAL PAIN SYNDROMES
1727	NSAID-NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
1728	ANTIPYRETICS
1729	MENSTRUAL PRODUCTS
1800	ANTIPARASITICS
1860	ANTIPROTOZOALS
1862	ANTHELMINTICS
1863	SCABICIDES/PEDICULICIDES
1864	ANTIMALARIALS
1900	RESPIRATORY TRACT
1940	ANTIASTHMATICS/BRONCODILATORS
1941	NASAL DECONGESTANTS

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1943	ANTITUSSIVES/EXPECTORANTS/MUCOLYTICS
1944	ANTIHISTAMINES
1945	COLD REMEDIES
1946	LOZENGE PRODUCTS
1947	CORTICOSTEROIDS-INHALATION/NASAL
2000	OTHER
2087	QUESTION OF USE
2095	PHARMACEUTICAL AIDS
2096	SURGICAL AIDS
2097	DENTAL PREPARATIONS
2098	DENTRIFICE/DENTURE PRODUCTS
2099	MOUTH PAIN, COLD SORE, CANKER SORE PRODUCTS
2100	HOMEOPATHIC PRODUCTS
9900	NO CLASS ASSIGNED
9998	MULTIPLE USES OF DRUG

Appendix 3

ICD-9-CM	
Code	Description
V01.1	Contact with or exposure to tuberculosis
V07.31	Prophylactic fluoride administration
V07.4	Postmenopausal hormone replacement therapy
V07.9	Unspecified prophylactic measure
V13.3	Personal history of diseases of skin and subcutaneous tissue
V15.0	Personal history of allergy, other than medicinal agents
V15.2	Personal history of surgery to other major organs
V15.82	Personal history of tobacco use
V22.2	Pregnant state, unspecified
V25.2	Encounter for sterilization
V25.9	Encounter for unspecified contraceptive management
V26.2	Procreative management, investigation and testing
V26.9	Unspecified procreative management
V40.3	Other behavioral problems
V40.9	Unspecified mental or behavioral problem
V41.6	Problems with swallowing and mastication
V42.0	Kidney transplant
V42.4	Bone transplant
V42.6	Lung transplant
V42.9	Unspecified organ or tissue transplant
V44.3	Colostomy
V45.6	Postsurgical states following surgery of eye and adnexa
V49.5	Other problems of limbs
V53.6	Fitting and adjustment of urinary devices
V58.1	Encounter or admission for chemotherapy
V58.9	Encounter for unspecified aftercare
V69.9	Problem related to lifestyle, unspecified
V74.1	Special screening examination for pulmonary tuberculosis
003.9	Salmonella infection, unspecified
005.9	Food poisoning, unspecified
008.8	Intestinal infections due to other organisms, not elsewhere classified
009.0	Infectious colitis, enteritis, and gastroenteritis
009.1	Colitis, enteritis, and gastroenteritis of presumed infectious origin
011.9	Pulmonary tuberculosis, unspecified
017.0	Tuberculosis of the skin and subcutaneous cellular tissue
033.9	Whooping cough, unspecified organism
034.0	Streptococcal sore throat
034.1	Scarlet fever
038.9	Unspecified septicemia
041.0	Streptococcus infection in conditions classified elsewhere and of unspecified site
041.1	Staphylococcus infection in conditions classified elsewhere and of unspecified site
041.9	Bacterial infection, unspecified
042	Human immunodeficiency virus [HIV] disease
049.9	Unspecified non-arthropod-borne viral diseases of central nervous system
052.9	Varicella without mention of complication
053.9	Herpes zoster without mention of complication

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
054.1 Genital herpes
054.2 Herpetic gingivostomatitis
054.9 Herpes simplex without mention of complication
075 Infectious mononucleosis
078.1 Viral warts
079.9 Unspecified viral and chlamydial infections
079.99 Unspecified viral infection
084.6 Malaria, unspecified
088.81 Lyme disease
098.0 Acute gonococcal infections of the lower genitourinary tract
099.9 Venereal disease, unspecified
110.0 Dermatophytosis of scalp and beard
110.1 Dermatophytosis of nail
110.2 Dermatophytosis of hand
110.3 Dermatophytosis of groin and perianal area
110.4 Dermatophytosis of foot
110.9 Dermatophytosis of unspecified site
111.0 Pityriasis versicolor
111.9 Dermatormycosis, unspecified
112.0 Candidiasis of mouth
112.1 Candidiasis of vulva and vagina
112.9 Candidiasis of unspecified site
117.9 Other and unspecified mycoses
126.9 Ancylostomiasis and necatoriasis, unspecified
127.4 Enterobiasis
128.9 Helminth infection, unspecified
133.0 Scabies
135 Sarcoidosis
136.9 Unspecified infectious and parasitic diseases
149.0 Malignant neoplasm of pharynx, unspecified
153.3 Malignant neoplasm of sigmoid colon
173.4 Malignant neoplasm of scalp and skin of neck
173.9 Malignant neoplasm of skin, site unspecified
174.9 Malignant neoplasm of female breast, unspecified
185 Malignant neoplasm of prostate
189.0 Malignant neoplasm of kidney, except pelvis
193 Malignant neoplasm of thyroid gland
199.1 Other malignant neoplasm, unspecified site (primary) (secondary)
208.9 Unspecified leukemia
238.2 Neoplasm of uncertain behavior of skin
239.6 Neoplasms of unspecified nature of brain
239.9 Neoplasms of unspecified nature, site unspecified
240.9 Goiter, unspecified
242.0 Toxic diffuse goiter
242.9 Thyrotoxicosis without mention of goiter or other cause
244.9 Unspecified hypothyroidism
246.9 Unspecified disorder of thyroid
250.0 Diabetes mellitus without mention of complication
250.9 Diabetes with unspecified complication
251.9 Unspecified disorder of pancreatic internal secretion

```

Appendix 3 continued

ICD-9-CM
Code Description

```

=====
253.9    Unspecified disorders of pituitary gland
255.4    Corticoadrenal insufficiency
256.3    Other ovarian failure
256.9    Unspecified ovarian dysfunction
259.9    Unspecified endocrine disorder
269.0    Vitamin K deficiency
269.2    Unspecified vitamin deficiency
269.9    Unspecified nutritional deficiency
272.0    Pure hypercholesterolemia
272.5    Lipoprotein deficiencies
272.9    Unspecified disorder of lipid metabolism
274.0    Gouty arthropathy
274.9    Gout, unspecified
275.4    Disorders of calcium metabolism
275.9    Unspecified disorder of mineral metabolism
276.1    Hyposmolality and/or hyponatremia
276.5    Volume depletion
276.6    Fluid overload
276.9    Electrolyte and fluid disorders not elsewhere classified
277.0    Cystic fibrosis
277.6    Other deficiencies of circulating enzymes
278.8    Other hyperalimentation
279.2    Combined immunity deficiency
279.4    Autoimmune disease, not elsewhere classified
279.9    Unspecified disorder of immune mechanism
280.9    Iron deficiency anemia, unspecified
282.6    Sickle-cell anemia
285.9    Anemia, unspecified
286.9    Other and unspecified coagulation defects
287.5    Thrombocytopenia, unspecified
289.9    Unspecified diseases of blood and blood-forming organs
290.0    Senile dementia, uncomplicated
295.3    Schizophrenia of the paranoid type
295.9    Unspecified schizophrenia
296.5    Bipolar affective disorder, depressed
296.7    Bipolar affective disorder, unspecified
296.8    Manic-depressive psychosis, other and unspecified
297.9    Unspecified paranoid state
298.9    Unspecified psychosis
300.0    Anxiety states
300.1    Hysteria
300.21   Agoraphobia with panic attacks
300.3    Obsessive-compulsive disorders
300.9    Unspecified neurotic disorder
302.71   Psychosexual dysfunction with inhibited sexual desire
304.9    Unspecified drug dependence
305.0    Alcohol abuse
305.1    Tobacco use disorder
305.9    Other, mixed, or unspecified drug abuse
306.4    Gastrointestinal malfunction arising from mental factors
=====

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
307.23 Gilles de la Tourette's disorder
307.42 Persistent disorder of initiating or maintaining sleep
307.49 Other disorders of sleep of nonorganic origin
307.5 Other and unspecified disorders of eating
307.81 Tension headache
308.0 Acute stress reaction, predominant disturbance of emotions
308.2 Acute stress reaction, predominant psychomotor disturbance
308.9 Unspecified acute stress
311 Depressive disorder, not elsewhere classified
312.89 Other specified conduct disorder, not elsewhere classified
312.9 Unspecified disturbance of conduct
314.0 Attention deficit disorder
314.9 Unspecified hyperkinetic syndrome
319 Unspecified mental retardation
322.9 Meningitis, unspecified
331.0 Alzheimer's disease
332.0 Paralysis agitans
333.99 Other extrapyramidal diseases and abnormal movement disorders
340 Multiple sclerosis
344.9 Paralysis, unspecified
345.9 Epilepsy, unspecified
346.9 Migraine, unspecified
347 Cataplexy and narcolepsy
349.0 Reaction to spinal or lumbar puncture
349.9 Unspecified disorders of nervous system
350.1 Trigeminal neuralgia
351.0 Bell's palsy
351.9 Facial nerve disorder, unspecified
354.0 Carpal tunnel syndrome
355.9 Mononeuritis of unspecified site
360.0 Purulent endophthalmitis
360.9 Unspecified disorder of globe
364.3 Unspecified iridocyclitis
365.9 Unspecified glaucoma
366.9 Unspecified cataract
367.2 Astigmatism
368.8 Other specified visual disturbances
368.9 Unspecified visual disturbance
369.8 Unqualified visual loss, one eye
369.9 Unspecified visual loss
371.9 Unspecified corneal disorder
372.3 Other and unspecified conjunctivitis
373.9 Unspecified inflammation of eyelid
373.11 Hordeolum externum
375.15 Tear film insufficiency, unspecified
375.9 Unspecified disorder of lacrimal system
379.9 Unspecified disorder of eye and adnexa
379.91 Pain in or around eye
379.93 Redness or discharge of eye
380.12 Acute swimmers' ear

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
380.4 Impacted cerumen
380.9 Unspecified disorder of external ear
382.9 Unspecified otitis media
386.0 Meniere's disease
386.12 Vestibular neuronitis
386.3 Labyrinthitis
386.9 Unspecified vertiginous syndromes and labyrinthine disorders
388.3 Tinnitus
388.7 Otalgia
388.8 Other disorders of ear
388.9 Unspecified disorder of ear
391.9 Acute rheumatic heart disease, unspecified
401.9 Unspecified essential hypertension
410.9 Acute myocardial infarction, unspecified site
413.9 Other and unspecified angina pectoris
414.0 Coronary atherosclerosis
416.0 Primary pulmonary hypertension
423.9 Unspecified disease of pericardium
424.0 Mitral valve disorders
427.0 Paroxysmal supraventricular tachycardia
427.1 Paroxysmal ventricular tachycardia
427.31 Atrial fibrillation
427.41 Ventricular fibrillation
427.69 Other premature beats
427.9 Cardiac dysrhythmia, unspecified
428.0 Congestive heart failure
428.9 Heart failure, unspecified
429.2 Cardiovascular disease, unspecified
429.8 Other ill-defined heart diseases
429.9 Heart disease, unspecified
435.9 Unspecified transient cerebral ischemia
436 Acute, but ill-defined, cerebrovascular disease
437.7 Transient global amnesia
437.9 Unspecified cerebrovascular disease or lesion
440.2 Atherosclerosis of native arteries of the extremities
440.9 Generalized and unspecified atherosclerosis
443.9 Peripheral vascular disease, unspecified
444.22 Arterial embolism and thrombosis of arteries of the lower
extremities
444.9 Arterial embolism and thrombosis of unspecified artery
446.5 Giant cell arteritis
447.9 Unspecified disorders of arteries and arterioles
451.2 Phlebitis and thrombophlebitis of lower extremities, unspecified
451.9 Phlebitis and thrombophlebitis of unspecified site
453.9 Other venous embolism and thrombosis of unspecified site
455.6 Unspecified hemorrhoids without mention of complication
458.9 Hypotension, unspecified
459.0 Hemorrhage, unspecified
459.9 Unspecified circulatory system disorder
460 Acute nasopharyngitis common cold

```


Appendix 3 continued

ICD-9-CM

Code Description

```

=====
462 Acute pharyngitis
463 Acute tonsillitis
464 Acute laryngitis and tracheitis
464.4 Croup
465.9 Acute upper respiratory infections of unspecified site
471.9 Unspecified nasal polyp
473.9 Unspecified sinusitis (chronic)
474.12 Hypertrophy of adenoids alone
474.9 Unspecified chronic disease of tonsils and adenoids
477.0 Allergic rhinitis due to pollen
477.8 Allergic rhinitis due to other allergen
477.9 Allergic rhinitis cause unspecified
478.1 Other diseases of nasal cavity and sinuses
478.2 Other diseases of pharynx, not elsewhere classified
478.7 Other diseases of larynx, not elsewhere classified
478.9 Other and unspecified diseases of upper respiratory tract
486 Pneumonia, organism unspecified
487.1 Influenza with other respiratory manifestations
487.8 Influenza with other manifestations
490 Bronchitis, not specified as acute or chronic
491.9 Unspecified chronic bronchitis
492.8 Other emphysema
493.9 Asthma, unspecified
496 Chronic airway obstruction, not elsewhere classified
501 Asbestosis
511.9 Unspecified pleural effusion
514 Pulmonary congestion and hypostasis
515 Postinflammatory pulmonary fibrosis
518.89 Other diseases of lung, not elsewhere classified
519.9 Unspecified disease of respiratory system
520.7 Teething syndrome
521.0 Dental caries
521.9 Unspecified disease of hard tissues of teeth
522.4 Acute apical periodontitis of pulpal origin
522.5 Periapical abscess without sinus
522.9 Other and unspecified diseases of pulp and periapical tissues
523.1 Chronic gingivitis
523.9 Unspecified gingival and periodontal disease
524.6 Temporomandibular joint disorders
525.1 Loss teeth due to accident/extraction/local periodontal disease
525.9 Unspecified disorder of the teeth and supporting structures
526.4 Inflammatory conditions of the jaws
526.9 Unspecified disease of the jaws
527.9 Unspecified disease of the salivary glands
528.2 Oral aphthae
528.3 Cellulitis and abscess of the oral soft tissues
528.5 Diseases of lips
528.9 Other and unspecified diseases of the oral soft tissues
529.9 Unspecified condition of the tongue
530.1 Esophagitis

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
530.11 Reflux esophagitis
530.2 Ulcer of esophagus
530.81 Esophageal reflux
530.9 Unspecified disorder of esophagus
531.9 Gastric ulcer unspecified as acute or chronic, without mention of
hemorrhage or perforation
532.9 Duodenal ulcer unspecified as acute or chronic, without mention of
hemorrhage or perforation
533.9 Peptic ulcer, site unspecified, unspecified as acute or chronic,
without mention of hemorrhage or perforation
534.4 Gastrojejunal ulcer chronic or unspecified with hemorrhage
534.9 Gastrojejunal ulcer unspecified as acute or chronic, without
mention of hemorrhage or perforation
535.5 Unspecified gastritis and gastroduodenitis
536.8 Dyspepsia and other specified disorders of function of stomach
536.9 Unspecified functional disorder of stomach
537.9 Unspecified disorder of stomach and duodenum
541 Appendicitis, unqualified
553.3 Diaphragmatic hernia
553.9 Hernia of unspecified site
555.9 Regional enteritis unspecified site
556.9 Ulcerative colitis, unspecified
558.9 Other and unspecified noninfectious gastroenteritis and colitis
562.0 Diverticula of small intestine
562.00 Diverticulosis of small intestine (without mention of hemorrhage)
562.01 Diverticulitis of small intestine (without mention of hemorrhage)
564.0 Constipation
564.1 Irritable colon
564.6 Anal spasm
564.9 Unspecified functional disorder of intestine
569.3 Hemorrhage of rectum and anus
569.9 Unspecified disorder of intestine
573.3 Hepatitis, unspecified
573.9 Unspecified disorder of liver
574.2 Calculus of gallbladder without mention of cholecystitis
575.0 Acute cholecystitis
575.9 Unspecified disorder of gallbladder
577.9 Unspecified disease of pancreas
586 Renal failure, unspecified
590.9 Infection of kidney, unspecified
592.0 Calculus of kidney
593.9 Unspecified disorder of kidney and ureter
595.9 Cystitis, unspecified
596.8 Other specified disorders of bladder
596.9 Unspecified disorder of bladder
599.0 Urinary tract infection, site not specified
599.7 Hematuria
599.9 Unspecified disorder of urethra and urinary tract
600 Hyperplasia of prostate
601.9 Prostatitis, unspecified

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
602.9 Unspecified disorder of prostate
604.9 Other orchitis, epididymitis, and epididymo-orchitis, without
      mention of abscess
607.84 Impotence of organic origin
608.9 Unspecified disorder of male genital organs
610.1 Diffuse cystic mastopathy
610.4 Mammary duct ectasia
611.0 Inflammatory disease of breast
611.8 Other specified disorders of breast
611.9 Unspecified breast disorder
614.2 Salpingitis and oophoritis not specified as acute, subacute, or
      chronic
614.9 Unspecified inflammatory disease of female pelvic organs and
      tissues
615.9 Unspecified inflammatory disease of uterus
616.0 Cervicitis and endocervicitis
616.9 Unspecified inflammatory disease of cervix, vagina, and vulva
617.9 Endometriosis, site unspecified
620.2 Other and unspecified ovarian cyst
620.8 Other noninflammatory disorders of ovary, fallopian tube, and broad
      ligament
621.8 Other specified disorders of uterus, not elsewhere classified
621.9 Unspecified disorder of uterus
623.9 Unspecified noninflammatory disorder of vagina
625.3 Dysmenorrhea
625.4 Premenstrual tension syndromes
625.9 Unspecified symptom associated with female genital organs
626.2 Excessive or frequent menstruation
626.4 Irregular menstrual cycle
626.9 Unspecified disorders of menstruation and other abnormal bleeding
      from female genital tract
627.2 Menopausal or female climacteric states
627.9 Unspecified menopausal and postmenopausal disorder
628.0 Female infertility associated with anovulation
628.9 Female infertility of unspecified origin
629.9 Unspecified disorder of female genital organs
634.9 Spontaneous abortion without mention of complication
644.0 Threatened premature labor
666.34 Postpartum coagulation defects, postpartum condition or
      complication
669.7 Cesarean delivery, without mention of indication
676.6 Galactorrhea associated with childbirth and disorders of lactation
680.2 Carbuncle and furuncle of trunk
680.9 Carbuncle and furuncle of unspecified site
681.0 Cellulitis and abscess of finger
681.02 Onychia and paronychia of finger
681.1 Cellulitis and abscess of toe
681.11 Onychia and paronychia of toe
681.9 Cellulitis and abscess of unspecified digit
682.2 Other cellulitis and abscess of trunk
  
```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
682.3 Other cellulitis and abscess of upper arm and forearm
682.6 Other cellulitis and abscess of leg, except foot
682.7 Other cellulitis and abscess of foot, except toes
682.8 Other cellulitis and abscess of other specified sites
682.9 Other cellulitis and abscess of unspecified site
683 Acute lymphadenitis
684 Impetigo
686.9 Unspecified local infection of skin and subcutaneous tissue
690 Erythematosquamous dermatosis
691.0 Diaper or napkin rash
691.8 Other atopic dermatitis and related conditions
692.6 Contact dermatitis/eczema due to plants [except food]
692.9 Contact dermatitis/eczema unspecified cause
695.3 Rosacea
696.1 Other psoriasis
698.9 Unspecified pruritic disorder
701.1 Keratoderma, acquired
701.4 Keloid scar
701.9 Unspecified hypertrophic and atrophic conditions of skin
702.8 Other specified dermatoses
703.0 Ingrowing nail
704.0 Alopecia
704.8 Other specified diseases of hair and hair follicles
704.9 Unspecified disease of hair and hair follicles
705.9 Unspecified disorder of sweat glands
706.1 Other acne
706.2 Sebaceous cyst
707.1 Chronic ulcer of lower limbs, except decubitus
707.9 Chronic ulcer of unspecified site
708.9 Urticaria, unspecified
709.9 Unspecified disorder of skin and subcutaneous tissue
710.0 Systemic lupus erythematosus
710.9 Unspecified diffuse connective tissue disease
711.96 Unspecified infective arthritis of lower leg
714.0 Rheumatoid arthritis
715.00 Osteoarthritis, generalized, site unspecified
716.66 Unspecified monoarthritis of lower leg
716.9 Arthropathy, unspecified
716.91 Arthropathy, unspecified, shoulder region
716.92 Arthropathy, unspecified, upper arm
716.94 Arthropathy, unspecified, hand
716.95 Arthropathy, unspecified, pelvic region and thigh
716.96 Arthropathy, unspecified, lower leg
716.97 Arthropathy, unspecified, ankle and foot
716.98 Arthropathy, unspecified, other specified sites
719.0 Effusion of joint
719.02 Effusion of joint, upper arm
719.03 Effusion of joint, forearm
719.06 Effusion of joint, lower leg
719.07 Effusion of joint, ankle and foot

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
719.09 Effusion of joint, multiple sites
719.4 Pain in joint
719.41 Pain in joint, shoulder region
719.42 Pain in joint, upper arm
719.45 Pain in joint, pelvic region and thigh
719.46 Pain in joint, lower leg
719.47 Pain in joint, ankle and foot
719.49 Pain in joint, multiple sites
719.5 Stiffness of joint, not elsewhere classified
719.56 Stiffness of lower leg joint, not elsewhere classified
719.58 Stiffness of other specified joint sites, not elsewhere classified
719.66 Other symptoms referable to lower leg joint
719.81 Other specified disorders of joint, shoulder region
719.9 Unspecified disorder of joint
719.91 Unspecified disorder of joint, shoulder region
719.93 Unspecified disorder of joint, forearm
719.94 Unspecified disorder of joint, hand
719.95 Unspecified disorder of joint, pelvic region and thigh
719.96 Unspecified disorder of joint, lower leg
719.97 Unspecified disorder of joint, ankle and foot
720.0 Ankylosing spondylitis
720.2 Sacroiliitis, not elsewhere classified
720.9 Unspecified inflammatory spondylopathy
722.1 Displacement of thoracic or lumbar intervertebral disc without
myelopathy
722.2 Displacement of intervertebral disc, site unspecified, without
myelopathy
722.6 Degeneration of intervertebral disc, site unspecified
722.9 Other and unspecified disc disorder
723.1 Cervicalgia
723.9 Unspecified musculoskeletal disorders and symptoms referable to
neck
724.3 Sciatica
724.5 Backache, unspecified
724.9 Other unspecified back disorders
725 Polymyalgia rheumatica
726.1 Rotator cuff syndrome of shoulder and allied disorders
726.11 Calcifying tendinitis of shoulder
726.32 Lateral epicondylitis
726.9 Unspecified enthesopathy
726.91 Exostosis of unspecified site
727.3 Other bursitis
728.85 Spasm of muscle
728.9 Unspecified disorder of muscle, ligament, and fascia
729.0 Rheumatism, unspecified and fibrositis
729.1 Myalgia and myositis, unspecified
729.2 Neuralgia, neuritis, and radiculitis, unspecified
729.5 Pain in limb
729.81 Swelling of limb
729.82 Cramp of limb

```

Appendix 3 continued

ICD-9-CM

Code Description

```

=====
729.9 Other and unspecified disorders of soft tissue
730.2 Unspecified osteomyelitis
730.96 Unspecified infection of lower leg bone
731.0 Osteitis deformans without mention of bone tumor
733.0 Osteoporosis
733.9 Other and unspecified disorders of bone and cartilage
734 Flat foot
735.4 Other hammer toe (acquired)
775.2 Neonatal myasthenia gravis
780.09 Other alteration of consciousness
780.1 Hallucinations
780.2 Syncope and collapse
780.3 Convulsions
780.4 Dizziness and giddiness
780.5 Sleep disturbances
780.52 Other insomnia
780.57 Other and unspecified sleep apnea
780.6 Fever
780.7 Malaise and fatigue
780.8 Hyperhidrosis
780.9 Other general symptoms
781.0 Abnormal involuntary movements
782.0 Disturbance of skin sensation
782.1 Rash and other nonspecific skin eruption
782.2 Localized superficial swelling, mass, or lump
782.3 Edema
782.9 Other symptoms involving skin and integumentary tissues
783.0 Anorexia
783.2 Abnormal loss of weight
783.6 Polyphagia
784.0 Headache
784.1 Throat pain
784.2 Swelling, mass, or lump in head and neck
784.7 Epistaxis
784.9 Other symptoms involving head and neck
785.0 Tachycardia, unspecified
785.1 Palpitations
785.2 Undiagnosed cardiac murmurs
785.6 Enlargement of lymph nodes
786.0 Dyspnea and respiratory abnormalities
786.09 Other dyspnea and respiratory abnormalities
786.2 Cough
786.5 Chest pain
786.6 Swelling, mass, or lump in chest
786.7 Abnormal chest sounds
786.8 Hiccough
786.9 Other symptoms involving respiratory system and chest
787.01 Nausea with vomiting
787.02 Nausea alone
787.03 Vomiting alone

```

Appendix 3 continued

ICD-9-CM
Code Description

```

=====
787.1    Heartburn
787.2    Dysphagia
787.3    Flatulence, eructation, and gas pain
787.7    Abnormal feces
787.9    Other symptoms involving digestive system
788.0    Renal colic
788.2    Retention of urine
788.3    Incontinence of urine
788.39   Other urinary incontinence
788.41   Urinary frequency
788.69   Other abnormality of urination
788.9    Other symptoms involving urinary system
789.0    Abdominal pain
790.6    Other abnormal blood chemistry
790.9    Other nonspecific findings on examination of blood
791.9    Other nonspecific findings on examination of urine
795.5    Nonspecific reaction to tuberculin skin test without
         active tuberculosis
799.2    Nervousness
799.8    Other ill-defined conditions, causes of morbidity and mortality
799.9    Other unknown and unspecified cause of morbidity and mortality
803.0    Other and unqualified skull fractures closed without mention of
         intracranial injury
805.8    Unspecified fracture of vertebral column without mention of spinal
         cord injury, closed
807.0    Fracture of rib(s), closed
814.0    Fracture of carpal bone(s), closed
816.0    Fracture of one or more phalanges of hand, closed
818.0    Ill-defined closed fractures of upper limb
820.8    Fracture of unspecified part of neck of femur, closed
826.0    Closed fracture of one or more phalanges of foot
827.0    Closed other, multiple, and ill-defined fractures of lower limb
839.8    Multiple and ill-defined dislocations, closed
840.4    Sprains and strains of rotator cuff (capsule)
840.9    Sprains and strains of unspecified site of shoulder and upper arm
842.0    Sprains and strains of wrist
844.9    Sprains and strains of unspecified site of knee and leg
845.0    Sprains and strains of ankle
845.1    Sprains and strains of foot
847.0    Sprains and strains of neck
847.2    Sprains and strains of lumbar back
847.9    Sprains and strains of unspecified site of back
848.3    Sprains and strains of ribs
848.9    Unspecified site of sprain and strain
873.4    Open wound of face, without mention of complication
879.8    Open wound(s) (multiple) of unspecified site(s) without mention of
         complication
879.9    Open wound(s) (multiple) of unspecified site(s), complicated
892.0    Open wound of foot except toe(s) alone without mention of
         complication

```

Appendix 3 continued

ICD-9-CM

Code Description

=====

894.0 Multiple and unspecified open wound of lower limb without mention of complication

910.2 Blister of face, neck, and scalp without mention of infection

915.8 Other and unspecified superficial injury of fingers without mention of infection

915.9 Other and unspecified superficial injury of fingers, infected

916.2 Blister of hip, thigh, leg, and ankle w/o mention of infection

917.8 Other and unspecified superficial injury of foot/toes w/o mention of infection

918.1 Superficial injury of cornea

918.9 Other and unspecified superficial injuries of eye

919.4 Insect bite of other/multiple/unspecified site, nonvenomous, w/o mention of infection

919.5 Insect bite of other/multiple/unspecified site, nonvenomous, infected

919.8 Other and unspecified superficial injury without mention of infection

923.0 Contusion of shoulder and upper arm

923.9 Contusion of unspecified part of upper limb

924.5 Contusion of unspecified part of lower limb

930.9 Foreign body on unspecified site of external eye

933.1 Foreign body in larynx

944.2 Burn of wrist(s) and hand(s) [second degree], blisters, epidermal loss

957.9 Injury to nerves, unspecified site

959.0 Face and neck injury, other and unspecified

959.1 Trunk injury, other and unspecified

959.3 Elbow, forearm, and wrist injury, other and unspecified

959.4 Hand injury, other and unspecified, except finger

959.5 Finger injury, other and unspecified

959.6 Hip and thigh injury, other and unspecified

959.7 Knee, leg, ankle, and foot injury, other and unspecified

959.8 Injury to other specified sites, including multiple

959.9 Injury to unspecified site

984.9 Toxic effect of unspecified lead compound

989.5 Toxic effect of venom

994.6 Motion sickness

995.2 Unspecified adverse effect of drug, medicinal and biological substance (due) to correct medicinal substance properly administered

995.3 Allergy, unspecified

995.69 Anaphylactic shock due to other specified food

996.8 Complications of transplanted organ

997.6 Late amputation stump complication, not elsewhere classified

999.3 Other infection following medical care, not elsewhere classified

888888 Blank but applicable

999999 Sample person did not know symptom or condition

References:

Denniston PL Jr, Epner JA, eds. Physicians GenRx, 1994: The Official Drug Reference. Smithtown, NY: Data Pharmaceutica Inc. 1993.

Product Information Management Branch. National Drug Code Directory. Vol. II. Rockville, MD: Food and Drug Administration. 1985.